Natural product-based pharmacological studies for neurological disorders

Abstract

Central nervous system (CNS) disorders and diseases are expected to rise sharply in the coming years, partly because of the world’s aging population. Medicines for the treatment of the CNS have not been successfully made. Inadequate knowledge about the brain, pharmacokinetic and dynamic errors in preclinical studies, challenges with clinical trial design, complexity and variety of human brain illnesses, and variations in species are some potential scenarios. Neurodegenerative diseases (NDDs) are multifaceted and lack identifiable etiological components, and the drugs developed to treat them did not meet the requirements of those who anticipated treatments. Therefore, there is a great demand for safe and effective natural therapeutic adjuvants. For the treatment of NDDs and other memory-related problems, many herbal and natural items have been used in the Ayurvedic medical system. Anxiety, depression, Parkinson’s, and Alzheimer’s diseases (AD), as well as a plethora of other neuropsychiatric disorders, may benefit from the use of plant and food-derived chemicals that have antidepressant or antiepileptic properties. We have summarized the present level of knowledge about natural products based on topological evidence, bioinformatics analysis, and translational research in this review. We have also highlighted some clinical research or investigation that will help us select natural products for the treatment of neurological conditions. In the present review, we have explored the potential efficacy of phytoconstituents against neurological diseases. Various evidence-based studies and extensive recent investigations have been included, which will help pharmacologists reduce the progression of neuronal disease.

1 Introduction

Information is sent across the body via a specialized network of neurons. Neurons use chemical and electrical signals to support the coordination of all fundamental aspects of life. When a neuron releases an electrical or chemical signal, it travels down its axon (a specialized projection) to the neighboring cell. These signals can be retained by root-like dendrites. There are around 86 billion neurons in the human brain. Hence, a growing fetus generates approximately 250,000 neurons each minute (Fields et al., 2020; Heiney et al., 2021). An enormous communication network is created because each neuron is connected to a thousand others. Neurons are the cells that make up the nervous system. Neurons are the cells in the brain responsible for transmitting and receiving signals. Despite their similarities to other types of cells, neurons are characterized by distinct physical and functional properties. Similar to the hundreds of kinds of animals and plants on Earth, thousands of distinct types of neurons exist. Neurons are not all the same in terms of structure, function, or genetics (Duan et al., 2020a; Yang et al., 2020). Neurons are further divided into three categories: sensory (carrying signals from the senses to the CNS), motor (carrying signals from the CNS to muscles), and interneurons (carrying signals from one place to another within the CNS) (Hor et al., 2018; Wan et al., 2018; Smolilo et al., 2019; Duan et al., 2020b). However, neurons come in five distinct varieties. Each exhibits a unique variation on the standard neuron shape.

Brain elements, including cognitive and motor neuron function, can be lost rapidly due to neurodegenerative illnesses, posing a significant problem for the elderly. Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are neurodegenerative illnesses (Angelucci et al., 2019; Jensen et al., 2020). Despite their various clinical manifestations, neurodegenerative symptoms share common traits and mechanisms. Regional cytosolic or nuclear protein aggregation is one of these characteristics (Xu et al., 2021). In AD, extracellular amyloid-beta (Aβ) plaques and intracellular hyperphosphorylated microtubule-binding tau inclusions form (Katsumoto et al., 2019; Roda et al., 2022). Some of the distinguishing features of these diseases are the accumulation of polyglutamine protein aggregates in HD and other repeat CAG-polyglutamine diseases, the intracellular storage of Aβ-synuclein in PD, and the inclusion of TAR DNA-binding protein (TDP)-43 transactive response in ALS, frontotemporal dementia, and other related disorders (Arnold et al., 2013; Toyoshima and Takahashi, 2014). Although a few genetic origins have been found, the primary factor is a complex mixture of genetic and environmental predisposition factors (a balance of hereditary and “sporadic” types in every major neurodegenerative condition). AD is a neurological condition that is the leading cause of dementia among the elderly (Pan et al., 2021a). The amyloid cascade hypothesis proposes that the accumulation of amyloid peptides as fibrils in the human brain is causally related to AD development (Ibrahim and Gabr, 2019). The binding of amyloid-β aggregates to neuronal and non-neuronal plasma membranes causes synaptic and neural network disruption, which is associated with cognitive abnormalities in patients with AD (Hampel et al., 2021). Symptoms include a progressive loss of memory and other cognitive skills as a result of the damage of specific forms of neurons and synapses, which leads to neuronal death (Angelucci et al., 2019). PD is a progressive neurological condition that leads to mortality. It affects 3% of the worldwide population over the age of 60 (Ball et al., 2019). There are two types of PD: familial (inherited in an autosomal dominant or recessive way) and sporadic (idiopathic), which is caused primarily by gene–environment interactions (Halperin and Healey, 2011; Verstraeten et al., 2015; Lill, 2016). Alpha-synuclein (SNCA), glucocerebrosidase (GBA), leucine-rich repeat kinase 2 (LRRK2), vacuolar protein sorting-associated protein 35 (VPS35), parkin RBR E3 ubiquitin protein ligase (PARK2), and phosphatase and tensin homolog-induced kinase 1 (PTHIK1) are the seven genes linked to familial (PARK7) (Kruse et al., 2012; Ma et al., 2013; Ankireddy and Kim, 2015; Kalinderi et al., 2016; Mursaleen et al., 2017; Zhao et al., 2018). These genes, as well as particular metabolites and PD-related biomarkers, have been utilized to investigate prospective early detection strategies for PD. The fundamental etiology of idiopathic PD is considered to be gene–environment interactions. Individuals exposed to the same environmental cause are impacted differently, resulting in various illness manifestations (Ball et al., 2019).

2 Common targets of neurological disorders

The various targets found in neurological conditions (Figure 1) that further can be explored for the drug treatment are mentioned as follows.

FIGURE 1

2.1 Amyloid and tau proteins

The tau and amyloid receptors have been tremendously researched as AD targets (Kent et al., 2020). The main aim is to lower amyloid levels and inhibit amyloid or tau accumulation. Various neuro-proteins, including APOE, APP, BACE (Aβ cleaving enzyme), PS1/2, secretase, and tau, play a key role in the pathogenesis of AD (Chen et al., 2017). Hence, studies are based on the development of novel compounds restricting the aforementioned process for the management of AD.

2.2 Cholinergic target

Various research findings have resulted in a facile grasp of the cholinesterase role inside the brain, along with the implementation of cholinesterase inhibitors in the treatment of AD (Stanciu et al., 2020). The further process of the newer generation of acetyl and butyryl cholinesterase inhibitors is being deliberated and scrutinized clinically for AD, resulting in the discovery of antioxidants, hormonal delivery, hypolipidemic compounds, anti-inflammatory drugs, and vaccinations (Santos et al., 2018).

The current study analyzes the common pharmacological targets and biological prospects for current and futuristic natural drugs. Multi-targeted techniques in oxidative stress and neuroinflammatory pathways, along with other target approaches and the extensive role of different phytoconstituents in neurodegenerative diseases (NDDs), are highlighted (Martins et al., 2020).

2.3 α-Synuclein protein

A 140-residue protein, presynaptic in the brain and called α-syn, is essential for the movement and synaptic vesicle fusion and controls dopamine (DA) release at presynaptic terminals. In the typical human brain and cerebral spinal fluid (CSF) fluid, α-syn has a physiological concentration of 1 μM and 70 pM, respectively (Domenighetti et al., 2022). When it binds to lipid vesicles, it transforms from its natural state of an unfolded monomer to α-helical conformations (secondary structure). This results in the misfolding and accumulation of α-syn upon destabilization in neurons. The monomeric protein α-syn is inherently disordered and exists in several conformational states. It is important for several vital metabolic pathways and increasing misfolding-related illnesses, most notably neurodegenerative disorders (Fields et al., 2019).

2.4 Chaperone proteins

Pharmacological chaperoning is emerging as a viable therapeutic strategy for the management of several disorders linked to single gene mutations. Small molecules known as chaperones attach to proteins, stabilize them against proteolytic breakdown, or guard them against heat denaturation. Additionally, they function similarly to molecular chaperones in aiding or hindering certain protein–protein complexes (Gouda et al., 2022). Several animal models of neurodegeneration have shown that distinct chaperone proteins are neuroprotective. Targeting the cytoplasmic chaperone Hsp90 and, by extension, enhancing the cellular response to stress may constitute a feasible therapeutic strategy for NDDs, although this hypothesis has to be proven and new drugs have to be developed (Lindberg et al., 2015).

2.5 Abelson (c-Abl) proteins

Cellular and oxidative stresses activate the protein Abelson (c-Abl), a member of the tyrosine kinase family. It is made up of the SH3, SH2, and catalytic domains. The function of c-Abl depends on where it is located within the cell. c-Abl promotes cellular adhesion with a survival mechanism inside the cytoplasm, but it also induces cell death inside the mitochondria and nucleus (Lindberg et al., 2015). Recent studies revealed that c-Abl is activated in response to amyloid beta fibrils and oxidative stress in AD and PD, as well as in animal models and neuronal cultures (Haron et al., 2021).

2.6 Mitochondrial region

It has been discovered that mitochondrial dysfunction is a universal trait of all neurological diseases. It is a major contributor to the onset and advancement of NDDs. Mitochondria play a pivotal role in health and disease by participating in various cellular processes, including maintaining a healthy intracellular Ca²⁺ balance, producing reactive oxygen species (ROS), initiating the intrinsic apoptotic pathway, and synthesizing heme and steroids. Mitochondria also play an important role in neural activity and plasticity and the formation and differentiation of brain cells (Werner and Olanow, 2022). Unusually formed and differentiated neurons emerge from defects in these pathways. Altered signaling of the apoptotic pathway has been linked to neurodegenerative disorders, such as HD, PD, ALS, epilepsy, schizophrenia, multiple sclerosis, neuropathic pain, and AD (Ikawa et al., 2021). Although the relationship between mitochondrial dysfunction and neurodegenerative disease onset and development is still not clearly understood, researchers are exploring treatments that control mitochondrial functioning to reduce neuronal damage and mutant protein aggregation (Jamwal et al., 2021).

2.7 Oxidative stress

Oxidative stress is still considered the primary treatment target in NDDs. It is important to investigate the several mechanisms that might considerably restore damage caused by ROS and thus slow or stop the progression of NDDs. The enzyme nicotinamide adenine dinucleotide phosphate oxidase is essential for oxidative stress and is a potential therapeutic target for the treatment of NDDs (Murphy and Hartley, 2018).

2.8 NMDA receptors

Neurodegenerative disorders, such as AD and PD, have attracted much attention regarding N-methyl-D-aspartate (NMDA) receptors and their functions in these conditions. Overactivation of NMDA receptors (NMDARs) mediates various elements of synaptic dysfunction in numerous central nervous system (CNS) disorders, prompting a great deal of focus on the development of drugs that can inhibit NMDAR activity (Marí and Colell, 2021; Rahman et al., 2022).

2.9 MAO enzyme

As an enzyme, monoamine oxidase (MAO) deaminates monoamines and other proteins. Nervous system diseases, such as AD, PD, ALS, HD, and depression-like disorders, are associated with the large formation of ROS caused by MAO hyperactivation. Although synthetic MAO inhibitors are currently used in clinical practice, they are linked to adverse events such as hepatotoxicity, cheese response, and hypertensive crisis. This has prompted the search for natural MAO inhibitors with a much more excellent safety profile (Gonzalez et al., 2015). The most prevalent neurodegenerative disorders are AD and PD. Based on current research into PD, type B MAO inhibitors, such as selegiline and rasagiline, show highly promising results as neuroprotective medicines. In cellular and animal models, neuronal cells are protected against death by these inhibitors. Stabilizing mitochondria, blocking the death signaling cascade, and activating the pro-survival anti-apoptotic Bcl-2 protein family and neurotrophic factors are all responsible for the neuroprotective actions (Naoi and Maruyama, 2010).

2.10 Neurofibrillary tangles

In neurofibrillary tangles, tau, a microtubule-associated protein, has become hyperphosphorylated. An imbalance between the activity of protein kinases and phosphatases acting on tau may occur even before neurofibrillary tangles form because phosphorylated tau proteins accumulate in neurons even before tangles form. To date, no in vivo development of neurofibrillary tangles has been observed in experimental models, and the molecular linkage between neurofibrillary tangle and senile plaque formation is poorly known (Mannan et al., 2022).

2.11 Angiotensin receptors

The rennin angiotensin system is made up of several different parts, including angiotensinogen, the (pro)renin receptor (PRR), angiotensin-converting enzyme 1 (ACE1), ACE2, angiotensin I (ATI), angiotensin II (ATII), ATII receptor 1 (AT11R), ATII receptor 2 (AT22R), and the Mas receptor (MasR). The rennin angiotensin system plays a crucial role in systemic and cellular pathways to maintain normal blood pressure, fluid balance, and cellular homeostasis. An ACE1/ATII/AT11R axis regulates oxidative stress and neuroinflammation pathways, whereas an ATII/AT22R and/or ACE2/Ang(1–7)/MasR axis enhances neuroprotection pathways. ATII is the primary effector of the RAS, and it exerts its impact by binding to AT11R and AT22R through two competitive arms (Srinivasan et al., 2022a).

2.12 COX enzyme

Several research studies have revealed the association between different pro-inflammatory cytokines and PD, and their findings suggest that immunological responses may explain a portion of PD etiology. Evidence supports the hypothesis that cyclooxygenase-2 (COX-2) is over-expressed in mouse models with PD. However, the same research showed that blocking COX-2 reduced the risk of PD by inhibiting the production of potentially harmful DA-quinones (Chinraj and Raman, 2022). Another research revealed that the neuronal cells of PD are severely damaged due to an invasion of T lymphocytes (Brochard et al., 2009).

Memory is a cognitive process in the brain that encodes, stores, and recalls information that has been received. Memory is crucial for learning and communicating with the surroundings (Fuloria et al., 2022). Subjective memory impairment is a frequent finding in adults, although the underlying condition is not detected in most of these patients. Memory impairment (MI) has various etiologies in the absence of physical or psychological disease, including being stressed, feeling ill, feeling melancholy, being exposed to air and noise pollution, adverse effects of certain medicines and substance addiction, and lifestyle factors, such as tobacco use, heavy alcohol consumption, poor physical exercise, and high-fat diet. Memory problems, often known as MI, are important markers for detecting syndromes and their underlying causes. AD, PD, HD, Korsakoff’s syndrome, and Creutzfeldt–Jakob disease are only a few examples (Sarris et al., 2014; Zlotnik and Vansintjan, 2019; Gao et al., 2022). With amnesia and dementia, MI mostly impairs declarative memory; however, this is not necessarily the case with dementia, defined as a decrease in two or more domains of cognition. In other words, dementia not only damages declarative memory but also affects other aspects of memory. Dementia has direct and secondary effects on memory (Vidyanti et al., 2022). Primary memory impairment can involve a deficit in declarative memory, which is one of the cognitive regions affected by AD. Memory capacity is harmed in a secondary case when there are cognitive abnormalities that might limit memory performance, such as attentional deficit (Callahan et al., 2022; Guo et al., 2022). There is currently no proven medication that can completely prevent MI from occurring. In contrast, memory enhancement treatments are critical for preserving a patient’s cognitive function to counteract MI risk factors (Gold and Budson, 2008; Wichansawakun et al., 2022).

3 Traditional holistic approach for the management of neurological disorders

Traditional medicines could be an alternative option to cure various neurodegenerative disorders because allopathic treatments are limited and have severe adverse effects. Indian ayurvedic medicine offers several plant-derived compounds that may be useful in future research, especially on neurological disorders. The ayurvedic system provides a holistic approach to managing different polyherbal formulations that act as antioxidants and reduce amyloid deposits and neuroprotective, anti-inflammatory, and immunomodulating compounds that alter neuroendocrine-immune activities, enhance memory, activate neurofunctions, and enhance the quality of life. A balanced lifestyle, good eating habits, socio-psychological support, Rasayanas, and psychotherapies as defined in Ayurveda have been recognized as effective approaches to prevent and treat AD and other neurodegenerative disorders (Rastogi, 2010; Ravikumar and Aittokallio, 2018; Sharma et al., 2018; Rastogi, 2019; Sharma et al., 2022).

Natural products, secondary metabolites, and bioactive molecules derived from plants, animals, and microorganisms are key sources of bioactive molecules that have been turned into disease remedies in many circumstances (Zucchella et al., 2018; Miranda et al., 2019; Ratcliffe et al., 2020). On land and at sea, nature has bestowed surplus resources (natural products) on humans. Natural products play an important role in disease prevention and health promotion for people and animals (Cragg and Newman, 2002; Mantovani et al., 2008; Cragg et al., 2009; Villa and Gerwick, 2010). These natural compounds have been shown to have various biological qualities, including antioxidant, anti-inflammatory, and anti-apoptotic capabilities (Villoslada et al., 2008). Natural products used in numerous preclinical models of neurodegenerative conditions have been further confirmed by in vitro and in vivo investigations. Phytoconstituents, such as polyphenolic antioxidants, are present in herbs, fruits, nuts, and vegetables, as well as marine and freshwater flora (Aboulwafa et al., 2019; Rehman et al., 2019). These phytoconstituents may help prevent neurodegeneration and improve brain memory and cognitive abilities. They are also thought to play a key role in preventing and treating neurodegenerative illnesses, including AD, epilepsy, and PD (Ratcliffe et al., 2020; Sharifi-Rad et al., 2020; Mendonça-Junior et al., 2021). The plants that show and prove their therapeutic action against neurological diseases are discussed in Table 1.

Neuroinformatics is the study of the neurological system via the development of databases and tools that aims to design and manage web-accessible databases of experimental and computational data and novel software tools that are necessary for understanding the nervous system in diseased and healthy states (Pu and Li, 2018; Usman et al., 2022). Brain imaging using positron emission tomography (Kaswan et al., 2021; Ruiz-Olazar et al., 2021), functional magnetic resonance imaging (Stefanovski et al., 2021; Li et al., 2022), electroencephalography (Wojcik et al., 2018; Shirbandi et al., 2021), magnetoencephalography (Gorina-Careta et al., 2021), and other methods; several electrophysiological recording methods; and clinical neurological data are examples of neuroinformatics (Sharma et al., 2019). In an interesting study, 679 flavonoid-based compounds and their 481 relative targets were screened, and their bioinformatic analysis exhibited multiple pharmacological pathways, especially for neuronal diseases. Flavone-based targets were remarkably augmented in mitogen-activated protein kinase (MAPK) signaling and neurotrophin signaling pathways, suggesting that natural flavone compounds possess biological effects on neuronal diseases (Qiu et al., 2018; Ravikumar and Aittokallio, 2018). Based on the pattern of substitution of phenyl rings and oxidation and saturation of pyran rings, different modified flavonoid-based compounds can be synthesized, thus exhibiting potent physico-chemical properties and biological activities acceptable for the effective management of neurological-related diseases (Figure 2) (Ayaz et al., 2019).

FIGURE 2

The concept of medications interacting with many targets has long been seen as undesirable, as it is inevitably related to negative side effects but theoretically can be safer compared to a single-hit target molecule (Hampel et al., 2021). Target-driven approaches often find a poor association between in vitro medication effects and in vivo effectiveness, thus finding a pivotal research scope. While understanding the underlying pathomechanisms of neurological and psychiatric disorders, searching for new biomarkers, and developing innovative therapies, translational research is one of the most important yet difficult fields for pharmacologists (Wan et al., 2018; Angelucci et al., 2019). Significant progress has been achieved in our understanding of the polygenic, complex, and heterogeneous disease pathways due to the advancement of disease models in vivo and in vitro (Xu et al., 2021). Diseases that can be studied through translational research include neurodegenerative disorders, such as AD, PD, multiple sclerosis, HD, and ALS, and psychiatric disorders, such as major depressive disorder, bipolar disorder, substance abuse disorder, post-traumatic stress disorder, anxiety disorder, schizophrenia, somatic symptom disorder, autism spectrum disorder, and hyperactive ataxia (Kaswan et al., 2021). There are clinician guides for using neuroscience to guide case framework, understand psychotherapeutic techniques, aid in treatment personalization and outcome prediction, and develop novel mechanistically targeted treatments for disorders (Shirbandi et al., 2021). We extensively added recent and updated key findings and additionally showed the applicability of natural products to improve their appropriate usage in neurological disorders, followed by the incorporation of various clinical studies and patents on phytoconstituents for neuronal diseases. This study focused on assessing various research studies related to the prevention and treatment of NDDs and provided evidence for the efficacy of natural products. It also sparked interest in the development of novel medications for neurological disorders derived from plant sources.

4 Phytoconstituents in different neurological disorders

4.1 Alzheimer’s disease

AD and dementia are diseases of the elderly society and have become one of the major concerns in health management because of the unattainability of medicinal treatment in this area (Liu et al., 2022). Pathophysiologically, AD is an accelerating neuro-degenerative disease, resulting in the change of behavioral patterns and cognitive defects, and is the recurring source of dementia in approximately 80% of the diseased population, expected to increase three times by 2050 (Zhang et al., 2021a). Various target receptors are responsible for this condition, including the scarcity of important neurotransmitter acetylcholine (ACh), accumulation of β-amyloid proteins, largely phosphorylated tau plaques, and variation in glutamate pathways, neuro-inflammation, and different pathways, which participate in the pathological mechanism of the particular diseased condition (Thomford et al., 2018). In fact, the following are the natural phytoconstituent-based drugs that have been accepted clinically in AD, such as cholinesterase inhibitors (tacrine, galantamine, donepezil, and rivastigmine) and glutamatergic system modulators (memantine). However, they have shown lesser symptomatic effect and hepatotoxicity with tacrine (Joshi et al., 2022).

The present pharmacological treatment depicts lesser symptomatic positive outcomes. Due to the multi-factorial causes, the advancement of novel molecules is aimed at multi-targeting therapy such as cholinesterase inhibition, anti-amyloid effects, β-secretase and MAO blockage, nitric oxide delivering ability and interactivity with cannabinoid, and NMDA or histamine receptors, contributing to an effective approach in AD. Interestingly, the clinically approved treatment for AD is based on natural phytoconstituents, and its recent developments are described in the following (Jankowska-Kieltyka et al., 2021).

By considering the “single-molecule multiple-target regimen” for the discovery of newer drugs in AD, natural molecules have found dominant interest. Regardless of the less-acknowledged success of synthetic compounds in AD, pharmacokinetics and pharmacodynamics (safety issues) are their crucial restricting steps (Stanciu et al., 2020). Contrarily, natural molecules extracted from herbal, nutritional, or marine origins have shown effectiveness in research studies based on a multi-targeting approach (Ciccone et al., 2021). Among many phytoconstituents, curcumin mitigates cognitive impairment symptoms by modulating inflammatory mechanisms in the brain, decreases free radical burden and metal ion chelation, and blocks Aβ aggregation. Furthermore, has proved to be a favorable candidate for AD and PD. Various flavonoids such as apigenin, luteolin, catechins, gossypetin, and myricetin have also been shown to inhibit Aβ accumulation in AD (Wang et al., 2018). Apigenin can modulate matrix metalloproteinases (MMP)-2 and 9, thus playing a neurodegenerative and neuroinflammatory role, especially in AD. Structure–activity relationship (SAR) research data on flavonoids observed that a catechol ring contributes to an important pharmacophoric moiety in multi-pharmacological activity, including AD. Other products, including alkaloids (huperzine A) and resveratrol, have different biological effects and can interact simultaneously with more than one target of this neurological disorder, showing better effectiveness (Patil et al., 2020; Fantacuzzi et al., 2022).

4.1.1 Berberine

Berberine is a natural compound in which quaternary ammonium salt of isoquinoline alkaloids extracted from different plant species such as Berberis aquifolium, B. vulgaris, B. aristata, Hydrastis canadensis, and Tinospora cordifolia (Neag et al., 2018). Several pharmacological actions of this compound are mentioned in the literature, such as antioxidant, cholinesterase inhibition, MAO inhibition, and hypocholesterolemic effect, along with fewer gastrointestinal side effects (Akbar et al., 2021). In a recent study, berberine (260 mg/kg, oral) has been reported to reduce Aβ₄₂ aggregation and tau hyperphosphorylation through remarkably mitigating endoplasmic reticulum (ER) stress (Wu et al., 2021). Similarly, Liang et al. and group discovered the effect of berberine in 3xTg AD (triple-transgenic AD) mice and observed that protein kinase RNA-like ER kinase/eukaryotic translation initiation factor 2α signal pathway was diminished, further declining Aβ growth and thus improving neuronal functions by mitigating ER and oxidative stress (Liang et al., 2021). In another study, berberine was found to lower MI effects as assessed in a triple-transgenic (3xTg) AD mouse model-based assay. Berberine (100 mg/kg, oral) could simultaneously target autophagic clearance and hyperphosphorylation of tau by regulating the Akt-glycogen synthase pathway (Chen et al., 2020).

4.1.2 Resveratrol

Resveratrol is a polyphenolic compound categorized as stilbenes extracted from plants after exposure to stress, injury, infection (fungal), or UV radiation (Perrone et al., 2017). This phytoconstituent has been reported to have antitumor, anti-inflammatory, cardiovascular, hypoglycemic, and neuro-protective effects with no adverse effects (Zhang et al., 2021b). Resveratrol is readily absorbed in the gastrointestinal lumen, simultaneously exhibiting lesser bioavailability because of its fast metabolism and elimination. Resveratrol plays a significant role in boosting non-amyloidogenic cleavage of the amyloid precursor protein, resulting in advancing the clearance of Aβ peptides and decreasing the degradation of neurons (Sergides et al., 2016). Resveratrol (15, 45, and 135 mg/kg) has been reported to block the cholinesterase effect in AD-based animal assays (Jia et al., 2017). A combination study of melatonin (80 mg/kg) with resveratrol (40 mg/kg) showed that melatonin augmented memory deficit effects in novel object recognition task (NORT) and passive avoidance task (PAT) assays of AD-based mouse models. In contrast, resveratrol enhanced only PAT response in respective animal studies (Jabir et al., 2018). Mehringer et al. explored phosphorylated resveratrol (Figure 3) for their AD-based neuronal properties and observed that these analogs could diminish the accumulation of proteins along with the fibrillation of Aβ42 and insulin based on in vitro studies. The in vivo drosophila fly model also showed prominent effects with decreased Aβ42 accumulation and enhanced neuroprotective locomotor action (Labban et al., 2021; Mehringer et al., 2022).

FIGURE 3

4.1.3 Curcumin

Curcumin is the most pivotal turmeric-based curcuminoid and is a popular yellow-colored Indian spice obtained from the rhizome part of Curcuma longa and corresponds to the ginger family (Hewlings and Kalman, 2017). Preclinical research has suggested curcumin to prevent or treat many disorders, such as colorectal cancer, cystic fibrosis, and inflammatory and neurological diseases (Jyotirmayee and Mahalik, 2022). Based on phase I clinical data, an oral curcumin dosage of 8,000 mg/day has not resulted in any major adverse effects besides mild nausea and diarrhea. However, excessive usage of this natural compound can harm the gut microbiome, thus obstructing the normal physiological and immunological processes (Gupta et al., 2013). The oral bioavailability of curcumin is relatively low, and many of its metabolites have been detected in plasma after oral intake (Lopresti, 2018). Many recent reviews have assessed the extraordinary role of curcumin in developing tau-focused therapeutics in AD, mainly due to the failure of most of the Aβ-based AD drugs in clinical trials (Sivanantharajah and Mudher, 2022). Current advances have revealed that the phenolic hydroxyl group of curcumin can contribute to the anti-amyloidogenic effect. Phenyl-substituted methoxy groups can show suppression of Aβ42 and APP (amyloid precursor protein), and hydrophobic interactions have also played an amplifying role. Furthermore, the elongation of phenyl rings can have decreased effect in patients with AD (Chainoglou and Hadjipavlou-Litina, 2020). Another systemic analysis carried out the correlation of the 74 target genes of curcumin with AD and experimented through Gene Ontology (GO) mechanism enrichment analysis and Kyoto Encyclopaedia of Genes and Genomes (KEGG). Five important genes were identified using the network pharmacological approach: RARA, APP, PRARG, STAT3, and MAPK1. Computational studies were also carried out to observe that curcumin has a prospective to attach with big active sites of PPARγ, observing better binding scores compared to other protein targets (Vijh et al., 2022). Another molecular docking study showed the molecular modeling studies of curcumin displaying a remarkable binding affinity toward mTOR, TrkB, LXR-β, TLR-2, ER-β, GluN2B, β-secretase, and GSK-3β, which are the critical modifiers of molecular and cellular pathways related to AD (Hannan et al., 2020). Recently, Utomo et al. verified curcumin-based compounds 1 and 2 (Figure 4) in Alzheimer’s Drosophila model and observed disassembled Aβ fibrils. The study further showed very low toxicity at 1 µM concentration in N2a cells (neuroblastoma) and prominently recovered its locomotor activity in AD model flies (Utomo et al., 2022).

FIGURE 4

4.2 Parkinson’s disease

The brain motor system is most primarily affected by PD, which causes inflammation and depletion of dopaminergic neurons inside the substantia nigra. A series of factors, including mitochondrial dysfunction, oxidative stress, protein misfolding during synthesis, excitotoxicity caused by different biochemical pathways (such as the glutamate pathway), lysosome impairment, chaperone-mediated autophagy, and the development of Lewy bodies as a result of protein misfolding, contribute to the onset of the disease (Amro et al., 2018). Associated protein (neurofilament) and protein targeting, such as ubiquitinated α-synuclein, are the components of cellular bodies. According to Braak’s staging, Lewy bodies are often located in the olfactory area and the lower part of the brain stem. However, as the illness advances, Lewy bodies also appear in the midbrain (substantia nigra) and forebrain, as well as the neocortex in an advanced stage. The most prevalent classes of phytochemicals with known antiparkinsonian actions include terpenes and numerous subtypes of polyphenols. Alkaloids, carbohydrates, acids (amino and fatty acids), and amides are a few more phytochemical groups containing representatives that have beneficial effects on PD (Lill and Klein, 2017; Zoey et al., 2021). Proinflammatory cytokines, such as prostaglandin E2, interleukin-6 and 1β, and nuclear factor of kappa cells, are reduced in expression, as nuclear and cellular inflammatory signaling, and phytochemicals suppress apoptosis (by reducing either caspases orα-synuclein aggregation), lower dopaminergic neuronal damage, and alleviate DA exhaustion. In order to increase the effectiveness and lower the biological side effects of PD, herbal compounds might be thought of as prospective pharmaceutical medications or as adjuvant therapy, along with traditional therapeutic procedures (Aliakbari et al., 2018).

The striatum has two primary output pathways. 1) The indirect route, which is carried out by inhibiting D2 DA receptors by DA in which the striatum sends GABA-mediated signals toward the neuronal cells in the lateral GP (GPe) and the GPe then sends signals to the STN, which sends glutamate-based excitatory signals to segment (internal) of GP (GPi), as well as SN pars reticulata (SNr). Rigidity and bradykinesia are clinical manifestations of the thalamocortical-spinal route suppressed by GPi and SNr. 2) Simultaneously, the unobstructed path is regulated by DA’s excitatory impact-bearing striatal receptors, and the lack of this neurotransmitter lessens the striatum’s ability to inhibit GPi and SNr (Merzougui et al., 2021).

Although the precise etiology and PD process are still unclear, there has been great progress in understanding the illness’s fundamental mechanisms. This was accomplished by research on genetics, experimental forms of PD, pathological and pharmacological abnormalities of PD, and novel findings on the structural characteristics and physiology of basal ganglia. In this study, we cover the pathophysiology of PD and the natural use of several herbal medicines, as well as their modes of action (Jankovic and Sherer, 2014).

Numerous studies on the use of various herbal remedies and natural items in the treatment of PD have been conducted over the past few years and have been explained below (Ion et al., 2021).

4.2.1 Curcuma longa

In India, Curcuma longa is frequently used as a medication for various health issues. It has been established that this plant has anti-inflammatory, antioxidant, chemotherapeutic, anti-proliferative, wound-healing, and antiparasitic properties. Curcumin, the plant’s active polyphenolic component, is assumed to be responsible for these properties (Nebrisi, 2021). Using fibroblasts from patients with PD, who have LRRK2 mutation, as well as healthy controls, curcumin is an effective treatment to address mitochondrial dysfunction in the condition. While post-curcumin treatment showed little impact, pre-curcumin treatment enhanced maximum and ATP-associated respiration. These findings are significant for the therapeutic use of curcumin because they suggest that it would be the most advantageous pre-treatment to toxin exposure. PD fibroblasts with the LRRK2 mutation and healthy control fibroblasts may benefit from pre-treatment with curcumin to prevent mitochondrial damage (Abrahams et al., 2021). Nerve regeneration and anti-apoptotic effects are considerably aided by phosphatidylinositol-3-kinase (PI3k)/protein kinase B (Akt) signaling mechanism and abrineurin pathway. According to recent studies, curcumin regulates the above-mentioned signaling pathways in neurodegenerative disease, positively affecting neuroprotection (Jin et al., 2022).

4.2.2 Resveratrol

Resveratrol, a natural polyphenol, is present in different plant species of grapes and berries. In PD etiology, altered PGC-1 activity and transcriptional dysregulation of its target genes were demonstrated by a recent study, suggesting that PGC-1 may represent a new target for therapeutic intervention. Resveratrol has been reported to increase mitochondrial action by activating multiple metabolic sensors, which in turn activates PGC-α. In addition, the resveratrol administration led to an uptick in the complex I and citrate synthase activity, a reduction in lactate content, an increase in baseline oxygen consumption, and the synthesis of mitochondrial ATP (Katila et al., 2022). These changes supported the transition from glycolytic to oxidative metabolism. Additionally, resveratrol administration increased macro-autophagic flux by activating a mechanism unrelated to LC3. The findings on PD fibroblasts from patients with early onset implied that resveratrol may have potential clinical use in some PD patients. In a different study, Su et al. investigated transgenic and chemically generated mouse PD models, including those caused by MPTP, rotenone, 6-OHDA, paraquat, and maneb (Su et al., 2021). Resveratrol’s neuroprotective effects were mostly focused on reducing oxidative stress and inflammation and improving mitochondrial dysfunction and motor function. Resveratrol also inhibits the production of the enlargement of mitochondria along with the compaction of chromatin and prevents the enlargement of mitochondria and condensation of chromatin (George et al., 2019).

4.2.3 Quercetin

Quercetin, a flavonol-type flavonoid, is present in several fruits and vegetables and is identified as a complementary treatment for PD. The neuroprotective action of quercetin is directly linked with its antioxidant activity, besides stimulating cellular defense against oxidative stress. Additional associated pathways are activating sirtuins (SIRT1) and stimulating autophagy, besides the induction of Nrf2-ARE and paraoxonase 2 (PON2) (Grewal et al., 2021). In another investigation by Josiah et al., the animal studies observed the promising efficacy of quercetin on NF-κB and IκKB gene expressions compared to the rotenone group only. Different research data have exhibited the potential of quercetin for PD by relieving oxidative stress, observing dopaminergic breakdown, and altering neuroinflammation, along with apoptosis (Josiah et al., 2022).

4.2.4 Walnut

The water extract of walnut (Juglandis semen) has exhibited pivotal neuroprotective action in various research studies. This extract was found to deplete ROS and NO (nitric oxide) growth, further blocking the loss of DA, thus showing exceptional recovery in patients with PD (Esselun et al., 2022). In another investigation by Yang et al., the walnut-derived polypeptide (TW-7) observed antioxidant action simultaneously initiating autophagy. They further investigated that TW-7 restricted the mitochondrial apoptosis through downregulation of the cytoplasmic cytochrome C, caspase-9, and cleaved-caspase-3 expression (Yang et al., 2022).

4.2.5 Olive leaves extract

Derivatives are isolated from olive leaves, including phenolic compounds, such as hydroxytyrosol, and flavonoids, such as luteolin, apigenin, and apigenin-7-O-glucoside, and their wide range of pharmacological activities, including several properties, such as neuroprotective, antioxidative, antibacterial, antiviral, anti-obese, and anti-inflammatory. The phenolic compounds isolated from olive lowered the syndrome (metabolic) associated with PD (Hadrich et al., 2022).

4.2.6 Myricitrin

Myricitrin, a naturally originated phenolic compound with antioxidant and anti-inflammatory properties, is also known as myricetin-3-O-rhamnoside. Myricitrin’s therapeutic potential was examined in a mouse brain model by Banerjee et al. In the mouse brain, myricitrin reduced MAO activity and increased DA levels. In the PD mouse model, myricitrin could lessen motor incoordination and elevate the DA levels in the striatum (Banerjee et al., 2022).

4.2.7 Baicalein

Baicalein is an active constituent in which Scutellaria baicalensis is its natural source. The alcohol extract of Scutellaria baicalensis has been reported to decrease nitric oxide (NO) and COX-2 levels (Jeong et al., 2011). This compound also restricts the accumulation of ROS, ATP degradation, apoptosis, and mitochondrial disruption based on rotenone-generated neuronal toxicity (PC12 cells) (Li et al., 2012). Zhao et al. showed that baicalein-treated mice exhibited lower depression-based symptoms after a monthly treatment, and its repeated usage induced α-synuclein dissociation, neuroinflammation blockage, and regulating the homeostasis of neurotransmitters (Zhao et al., 2021). In another study, Song et al. investigated that baicalein can also inhibit the MAO enzyme, and its blocking action on oxidative stress is governed by ERK inhibition in PD (Song et al., 2021; Xu et al., 2022).

4.2.8 Glycyrrhizin

The primary active component of licorice roots and rhizomes (Glycyrrhiza glabra L.) is glycyrrhizin, which is typically used to treat inflammatory illnesses or even as a tonifying herbal remedy. Ren et al. reported inhibition of the degeneration of DA neurons, reduction of the count of apoptotic cells in the zebrafish brain, prevention of the loss of their vasculature as well as disordered vasculature, and suppression of the locomotor impairment to exert an anti-PD effect on MPTP-induced PD in zebrafish (Ren et al., 2022).

4.2.9 Chicoric acid

A polyphenolic acid called chicoric acid (CA), which is derived from the purple coneflower (Echinacea purpurea) and chicory, has been promoted as a nutraceutical to fight infections, inflammation, and obesity. Wang et al. showed that oral pretreatments of CA significantly prevented the motor dysregulation and death of nigrostriatal dopaminergic neurons exacerbated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), including the inhibition of glial hyperactivation and the increase in striatal neurotrophins. It may be inferred that CA showed neuroprotective effects on mice with MPTP-induced PD. These benefits may have been caused by altering the gut microbiota and reducing inflammation along the brain–gut axis (Wang et al., 2021).

4.3 Amyotrophic lateral sclerosis

There are broadly two types of ALS: sporadic and familial types. The family variety (5%–10%) has a genetic component but is genetically inherited, whereas the irregular type, which is prevalent (90%–95%), is not inherited. Various neurological conditions, including ALS, are characterized by the degeneration of both motor neurons (upper and lower). Intraneuronal protein aggregates, including protein TAR DNA-binding, superoxide dismutase, and fused in sarcoma, may interrupt normal protein homeostasis and cause ALS and cellular stress (Chandran et al., 2022). These proteins have been thoroughly discovered in ALS animal models and pathological examinations of individuals. Muscle twitching, cramping, soreness, and weakness are static analyses of ALS. Patients eventually develop dysphagia (difficulty swallowing), dysarthria (difficulty speaking), and dyspnea (difficulty breathing) in the advanced stage of the disease. Diet and environmental toxins have also been researched for their links to ALS. For ALS treatment, multidisciplinary methods are reported to be beneficial (Kim and Taylor, 2017; Anakor et al., 2022).

4.3.1 Mecasin

Mecasin, traditional medicine that originated in India, has been shown to have various biological effects in vivo and in vitro. It also possesses anti-inflammatory properties based on previous investigations and has been discovered for ALS by Kim et al. Mecasin was found to lessen symptom development without causing significant side effects, and the long-term effects of the drug are currently being studied in a phase IIb clinically (Kim et al., 2022).

4.3.2 Morin

It is possible to isolate the yellow chemical component known as morin from the leaves of Psidium guajava, Maclura pomifera, and Maclura tinctoria. Srinivasan et al. studied the effectiveness of flavonoids against amyloids, such as morin, myricetin, and epigallocatechin gallate. Additionally, it was determined that morin has a significant therapeutic potential for developing extremely effective inhibitors for reducing deadly and incurable ALS (Srinivasan et al., 2022b).

4.3.3 4-Hydroxyisoleucine

The insulin sensitivity of rodents is improved by the bioactive amino acid (4-hydroxyisoleucine, HI) extracted from Trigonella foenum-graecum. This study focused on brain IGF1/GLP-1 activation, and a study evaluating adult Wistar rats with ALS-like signs found that 4-HI had neuroprotective properties that had been treated with methyl mercury (MeHg⁺). Additionally, evidence points to the neuroprotective advantages of 4-HI in minimizing MeHg⁺-induced behavioral changes, chemical alteration in neurons, and histological impairments in ALS in rats exposed to methylmercury (Shandilya et al., 2022).

4.4 Huntington’s disease

The neurological abnormality known as HD is inherited in an autosomal dominant manner and is monogenic. Patients and their families find the illness state traumatizing due to its inheritance pattern (autosomal dominant), progressive nature, and mix of physical, cognitive, and behavioral deficits (Lum et al., 2021). HD is a pathological condition caused by an enlarged CAG trinucleotide repeat in the gene (HTT5) on the chromosome (Yang et al., 2020), which codes for aberrant huntingtin, a potentially pathogenic protein with several functions. The enlarged CAG repeat seen in the mutant protein’s unique polyglutamine pattern is recognized to be hazardous and causes the death or malfunction of neuronal cells (Träger et al., 2015). The striatum neurons are vulnerable to this mutant protein, although HD has been shown to affect the whole brain and body. Exon 1 of the mutant huntingtin protein directly affects transport (axonal), homeostasis (protein), and mitochondrial functioning. The mutant protein’s propensity to aggregate also directly affects these processes. Abnormal huntingtin protein causes neuronal death through several methods. The alternative theory links HD’s neuronal damage to neurotrophic factor losses, glutamate excitotoxicity, and toxic consequences of repetitive associated non-ATG translation mechanisms (Kay et al., 2015).

Memory loss and motor loss of coordination caused by 3-nitropropionic (3-NP) acid were greatly reduced by natural precursors. Reduced lipid peroxidation, enhanced endogenous antioxidants enzymatically, decreased activity (acetylcholinesterase), and increased mitochondrial generation have significantly reduced biochemical changes. Interestingly, 3-NP-induced damage to the striatum was lessened after therapy with certain natural ingredients, as seen by histology. Overall, antioxidant and anti-inflammatory characteristics, maintenance of mitochondrial function, suppression of apoptosis, and activation of autophagy in natural products provided varied levels of neuroprotection throughout preclinical trials of HD (Lum et al., 2021).

4.4.1 Embelin

Embelin’s ability to fortify neurons against 3-NP-induced exploratory HD in rats was examined by Dhadde et al. in which vehicle/embelin was pretreated in adult Wistar rats (doses of 10 and 20 mg/kg p.o.) for a week. Furthermore, embelin significantly reversed behavioral changes, improved antioxidant status, and repaired striatal neuronal damage brought on by 3-nitropropionic acid (Kundap et al., 2017). In an interesting study, embelin and levodopa were analyzed for PD and HD animal studies, which were shown to mitigate oxidative and neuroinflammatory stress. Tyrosine hydroxylase and Nurr1 protein levels were significantly recovered. In silico computational studies between embelin and α-syn fibrils were also demonstrated, which validated the strong affinity of embelin approaching α-syn with the help of hydrogen bonding with Lys45(D) and His50(D) residues of α-syn (Figure 5) (Ramachandra et al., 2022).

FIGURE 5

4.4.2 Curcumin

In India, Curcuma longa is frequently used as a medication for several health issues. It has been established that this plant has several properties and is a potential candidate for antioxidant, anti-inflammatory, wound healing, chemical, therapeutic, anti-proliferative, and antiparasitic properties (Mohammadi et al., 2022). Curcumin, the plant’s active polyphenolic component, is assumed to be responsible for these properties. Curcumin’s effectiveness was examined by Aditi et al. in a Drosophila model of HD. The injection of curcumin was observed to increase locomotor performance and enhance lifespan in HD flies with advanced illness stages and reduce high reactive oxygen species levels in adult adipose tissue of sick flies (Aditi et al., 2022). The effectiveness of melatonin and curcumin in avoiding the motor deficit and disordered eclosion behavior in the Drosophila model of HD was examined by Khyati et al. It can also be deduced that melatonin (100 μg) and curcumin dramatically enhanced the abilities of HD flies to move around and behave in an enclosing manner, restoring the 24 h rhythm of mRNA expression of period and timeless to normal (control) levels (KhyatiMalik et al., 2021).

4.4.3 Lactuca sativa

Malik et al. produced extracts (ethanolic) of the leaves of three different Lactuca sativa (LS) cultivars and assimilated them using HPLC according to their quercetin concentration. The extract with the highest activity level was progressively separated in increasing polarity employing organic solvents (hexane, ethyl acetate, and n-butanol) and an aqueous solvent. It was further concluded that improved behavioral and biochemical indicators demonstrated the greatest reduction of 3-NP-induced HD-like symptoms (Malik et al., 2022).

4.4.4 Baicalein

The neuropharmacological efficiency of baicalein against QA-induced hypertension was assessed in recent research. In the striatum of HD-induced rats, naturally found baicalein, technically known as 5,6,7 trihydroxy flavone, including Scutellaria baicalensis and Oroxylum indicum (edible plants), has a stronger neuroprotective effect when administered intraperitoneally in doses of 10 and 30 mg/kg. Further analysis reveals that the neuroprotective effectiveness of baicalein exhibits the advancement of psychological and cognitive alterations spurred on by QA (Purushothaman and Sumathi, 2022).

4.4.5 Ugni molinae berries

Arancibia et al. discovered that extracts (phenolic rich) from murtilla berries of the 19-1 genotype significantly decreased peptide (polyglutamine) accumulation amounts, corresponding with the regulation in the expression patterns of proteins, which are related to autophagy and thus promising in HD therapy. Berries were extracted by exhaustive maceration with increasing polarity solvents (Pérez-Arancibia et al., 2021).

4.5 Epilepsy

Epilepsy is a neurological disease identified with attacks of altered brain responses, resulting in convulsions and seizures, and has affected around 50 million people worldwide (Pearson-Smith et al., 2017). A series of pharmacological events include cognitive impedance and oxidative stress, further contributing to epilepsy-linked recurrent seizures (Mao et al., 2019). In addition, Mao et al. explored the pharmacological mechanism at the molecular level via different redox-related neurological cell death modalities in onset seizures. The group also analyzed ferroptosis, a newly discovered lipid ROS-dependent regulatory cell death, which is likely to be a critical mechanism for unfolding epileptic phenotype (Rho and Boison, 2022).

Epileptic seizures also arise due to the imbalance in the excitation/inhibition response of decreased GABA receptors and the rise in glutamatergic transmission (Karim et al., 2021). Thus, phytoconstituents maintaining this balance [in between the GABA (brain neurotransmitter) and glutamate and blocking of glutamate receptors] will have an efficacious antiepileptic response compared to allopathic antiepileptic drugs showing major side effects among which impairment (cognitive) is undesirable (Kaur et al., 2021). Natural products have exhibited experimentally encouraging results in animal models based on epilepsy. An interesting study discovered the modifications of GABA, GABA_A, and GABA_B targets in the cerebral cortex of epileptic rats, along with the pharmacological application of Bacopa monnieri. This plant variety and bacoside-A reversed epilepsy-associated symptoms exhibiting the diminishing role of GABA receptors in epilepsy recurrence (Mathew et al., 2012).

4.5.1 Cannabidiol

Cannabidiol (a phytocannabinoid) is a natural constituent in the Cannabis sativa, also known as cannabis or hemp, comprising 80 different forms. One of the cannabidiol forms was approved as an anti-seizure drug in the United States in 2018 (Ryan, 2020). Cannabidiol has been proved via recent studies to exhibit anti-epileptic and anticonvulsant activities in acute animal models of seizures. However, their detailed pharmacological pathways remain under investigation (Devinsky et al., 2014). Gray et al. proposed three different pharmacological targets for cannabidiol, including transient receptor potential vanilloid-1, G protein-coupled receptor-55, and equilibrated nucleoside transporter 1, as this phytoconstituent has an attraction for more than one target resulting in neurological excitation applicable in epilepsy (Gray and Whalley, 2020). Concomitantly, cannabidiol was investigated along with other anticonvulsant drugs for its safety, pharmacokinetics, and drug–drug interaction with the help of double-blinded placebo-controlled trials in the recurrent epilepsies in pediatric patients, not just in the epileptic encephalopathy. Cannabidiol administration was observed to be safe and well-tolerated, and new levothyroxine–cannabidiol interaction was reported (Raucci et al., 2020; Cáceres Guido et al., 2021). The structural modification of cannabidiol phytoconstituent majorly comprises its alkyl side chain and the incorporation of phenolic hydroxyl groups on the propenylcyclohexene moiety. The SAR-based studies on cannabidiol, especially on neurodegenerative disorders, are well-reviewed by various groups. Thus, this phytoconstituent has shown great potential in neuropharmacological action (Morales et al., 2017; Prandi et al., 2018; Yousaf et al., 2022).

4.5.2 Apigenin

Apigenin is a flavonoid with several anti-inflammatory, antioxidant, and neurological effects (Salehi et al., 2019). Apigenin and its derivatives are obtained from several plants, such as fruits, vegetables, nuts, citrus, tea, chamomile, thyme, celery, and celeriac, in their glycosidic form (Ginwala et al., 2019). Shao et al. discovered that apigenin could alleviate myeloperoxidase-related oxidative stress and block the ferroptosis of neurological cells. The study developed a multifunctional brain-imaging fluorescence tool and explicated the role of HClO (endogenous hypochlorite) generation by myeloperoxidase in the physiology of epileptic seizures, thus inventing new antiepileptic agents for the prevention and treatment of epilepsy (Shao et al., 2020). The cognitive deficit, a common symptom in epilepsy, was treated with apigenin. Hashemi et al. concluded the biological role of this phytoconstituent in restoring memory deficiency (apigenin significantly increased the number of living neurons in the hilus), thus showing potent anticonvulsant and neuroprotective action (Hashemi et al., 2019).

4.6 Depression

Depression is a neurological condition that affects people of all ages worldwide. It is distinguished by emotional, behavioral, health, cognitive capabilities, and behavioral and sleep patterns (Wang et al., 2007). The family and medical history of the patient, early childhood traumas, brain anatomy, and drug consumption are all key contributing variables. Depression is the main cause of disability and a substantial contribution to illness, according to a new World Health Organization report. Multiple complicated biological processes are involved in the pathophysiology of depression (Duman and Voleti, 2012; Zhang et al., 2019). MAPK and cyclic adenosine phosphate signaling are globally accepted to be connected with depression progression, which has sparked much interest in antidepressant research (Pandey et al., 2013; Ekor, 2014). The traditional medical system, which is based on natural ingredients from numerous sources, provides a framework for several commercial depression treatments (Pan et al., 2021b; Álvarez et al., 2022). Metabolic extracts and metabolites derived from many medicinal plants have been shown to have antidepressant effects. In addition to leaves, flowers, and fruits (powdered or unripe), the metabolic extracts are generated from many plant components, such as stem bark, bulb (powdered), the whole plant (seed), petal (stigma), and rhizome (hypocotyl) (Singh et al., 2003; Fakhri et al., 2021; Ranjbar et al., 2022). Collectively, some researchers carried out antidepressant action or neuroprotective benefits by several methods that target the neurological signaling pathways or molecules responsible for depressive illnesses (Lu et al., 2022; Zarneshan et al., 2022). Natural compounds produced from various parts of the plants with a common mode of action are addressed in Table 2. This mechanism includes MAO (MAO-A and MAO-B) inhibitory activity and interactions with dopaminergic (D2), serotonergic, GABA (gamma-aminobutyric acid), adrenergic (α1), and noradrenergic receptor system interactions (Ekor, 2014).

4.7 Anxiety

Anxiety disorders are common, incapacitating, frequently chronic, and very co-morbid conditions (Saha et al., 2022). Plant-based medications may provide an extra safe and useful option in addition to traditional pharmacotherapies and psychological therapy, which are the front-line techniques. The term “anxiolytics” refers to phytotherapeutic treatments that may be helpful for anxiety disorders. These treatments typically have effects on the GABA system (Sarris, 2007; Sarris and Kavanagh, 2009), either affecting ionic channel transmission through voltage-gated blocking, altering membrane architecture (Greenfield, 2022), or, less frequently, binding to benzodiazepine receptor sites (such as GABA-a) (Awad et al., 2007), inhibiting GABA transaminase or glutamic acid decarboxylase (Rastogi et al., 2016). Preclinical research in this field has been widely explored, especially by nations such as China, India, Brazil, the United States, Spain, and Germany. Over the past several decades, clinical studies have been undertaken on various plant-based medications for different anxiety and mood disorders. Preclinical research is essential because it frequently expands on existing knowledge of the traditional uses of plant medicines and informs possible human applications. Table 3 discusses medicinal plants used in clinical trials for anxiolytic effects.

4.8 Spinal cord injury

Mechanisms such as multiple cellular and molecular are activated by acute spinal cord injury (SCI). Su et al. inquired how effectively the Jisuikang (JSK), a traditional drug, works as a treatment in a rat model with established SCI. High-performance liquid chromatography in conjunction with photodiode array detection, electrospray ionization-mass spectrometry, and phytochemical fingerprinting of JSK was used. Additionally, JSK seems to target several pathways (biochemical and cellular) to promote functional recovery and enhance the results of SCI (Su et al., 2013; Islam et al., 2022). To evaluate the therapeutic effects of ethanolic extract of Mucuna pruriens (MP) in treating SCI, Chandran et al. used the widely researched standardized Multicenter Animal Spinal Cord Injury Study animal model of the contusive spinal cord. Additionally, MP, at equivalent dosages, was found to be very beneficial in reducing inflammation and/or oxidative stress in various disease circumstances (Rastogi, 2014).

5 Role of natural products as biomarkers in neuronal diseases

Using biomarkers of neurodegeneration and neuronal dysfunction can enhance the precision of diagnosis, the ability to track disease progression, prognosis, and the efficacy of therapeutic interventions. Neurological biomarkers are present in the CSF but rarely or at undetectable levels in the blood. Different proteins presented in the CSF, such as neurofilament proteins, tau, and tar DNA-binding protein (TDP-43), have been considerably applied markers to monitor the CNS activity (Viswambharan et al., 2017).

Natural substances have rarely been used as biomarkers in neurodegenerative disorders. However, many biomarkers have been utilized to disclose the molecular pathways of plant extracts for the therapy of NDDs. For example, plasma Aβ40 levels were used to detect the effect of curcumin on AD (Hardy and Selkoe, 2002; Baum et al., 2008). Aβ40 belongs to the βAPP gene, the first AD susceptibility gene found, which encodes a glycosylated transmembrane protein of 770 amino acids in its longest isoform. The amyloid cascade theory postulates that an increase in the production of the proteins would result from a mutation in the βAPP gene, with more of the protein eventually broken down to produce the poisonous β-amyloid peptides (Aβ) (Huang et al., 2014). Aβ was also used in a Huperzia serrata (Chinese herb) study in the treatment of AD. Cholinesterase inhibitor isolated from Huperzia serrata was reported to decrease levels of soluble and insoluble β-amyloid and amyloid plaques in AD mice (Ghodsi et al., 2022a; Mitra et al., 2022).

In the case of PD, α-synuclein aggregation has been used as a biomarker in various in vivo studies. Basically, α-synuclein gene is most commonly expressed on elongated arm of chromosome 4 and is a characteristic of PD and also leads to faster progression of the disease. They occur in most forms, including the rare early-onset familial form of PD. A study reported that curcumin extract prevented α-synuclein aggregation and fibrillation in animal models of PD (Bakhtiari et al., 2017).

6 Role of bioinformatic studies of plant metabolites in neuronal diseases

Several plants have been used in medicine for neuronal diseases since historical times, and some natural extracts have been developed to commercial medical products. The conventional method of the discovery of plant-based pharmaceuticals is frequently time-consuming and costly. The fast development of high-throughput technology has made it difficult for these labor-intensive methods to stay up. Bioinformatics is vital in the era of high-volume, high-throughput data creation in biosciences. In the realm of drug design and discovery, this has typically been the case. However, the potential use of bioinformatics techniques that can harness plant-based knowledge has received little attention so far. Bioinformatics research has benefited medicinal plant research. In medicinal plant research, the application of bioinformatics techniques leads to faster and potentially more cost-effective discoveries of plant-based treatments.

Most bioinformatic studies of plant metabolites in neuronal diseases have focused on flavonoids. Flavonoids are a family of phenolic substances. This group of phenolic substances has been reported to affect neuroprotection in AD (Mohebali et al., 2018; Sharma et al., 2021). Different side chains may considerably impact the biological activities of flavonoid subclasses, according to systematic correlations between fragments of the chemical structure and biological effects. Flavonoids might considerably enhance the pathways of HD and AD compared to other natural plant products. In addition, systemic examination of targets for various flavonoid subclasses revealed that targets such as MAPT, APEX1, and ALDH1A1, which are strongly associated with the nervous system, were considerably enriched in nearly all flavonoid subclasses. In this situation, the flavonoid multimodal therapeutic potential suggests their value in nervous system medication discovery (Qiu et al., 2018).

7 Limitations

Therapeutic efficacy in human patients remains uncertain and limited, although natural products or plant extracts with antioxidant activity have shown excellent efficacy in in vitro and in vivo animal models. This might be attributed in part to the fact that most clinical studies focus on single compounds. In contrast, plant extracts containing a range of secondary metabolites are more commonly investigated in studies preceding clinical trials. The combination of several active components in extracts can have additive or synergistic effects, resulting in enhanced antioxidant or disease-modifying activities. In addition, clinical trials examine a wide range of subjects with various environmental and genetic origins, as well as various illness symptoms and, in some cases, disease stages. It can be interesting to look at specific people or small groups who show substantial improvement rather than the overall importance of the entire participant population to see why some respond to the treatment and others do not. Furthermore, most clinical studies on natural antioxidants (i.e., natural products or plant extracts) have focused on behavioral or cognitive improvements in patients. In contrast, relatively few trials have properly examined molecular signs of sickness or oxidative stress (Pohl and Kong Thoo Lin, 2018).

8 Patent overview

Varied medicinal plant species have been explored in neuronal disorders in the conventional system of natural medicines, and interestingly, unknown species are yet to be scientifically explored. The emphasis on research in the field of herbal compounds in neurological disorders expanded after phytoconstituents were used as a basis for the human treatment of several neurological disorders (Table 4). Ravid et al. formulated a combination of Uncaria rhynchophylla herb and an antidepressant or anxiolytic drug therapy for treating or preventing anxiety, stress, depression, and/or symptoms. The combinations, therefore, elicit fast on-set responses in patients (Ravid, 2022). Ichim et al. formulated a nutraceutical of green tea extract and/or Nigella sativa, pterostilbene, and/or sulforaphane to overcome treatment resistance of the currently used antidepressants (Thomas et al., 2022). Thamaraikanet et al. prepared a phytochemical extract containing indole alkaloids. Camalexin in aldehyde dehydrogenases mediated benomyl-induced PD. The formulation provides a suitable multi-targeted molecule with antioxidant, neuroprotective, and minimal side-effect properties that can be used as an anti-PD drug (Manasa et al., 2022). Sudhakara Sastry et al. formulated a therapeutically effective nano-polyherbal composition comprising herbal extracts, such as Allium sativum, Bacopa monniera, Citrus lemon, Citrus sinensis, Curcuma longa, Cyperus rotundus, Lycopersicon esculentum L., Mucuna pruriens, Nardostachys jatamansi, Nigella sativa, Prunus dulcis, Psidium guajava, Sesame indicum, Vicia faba, Vitis vinifera, Withania somnifera, and Zingiber officinale using the phytonanoceutics method, thereby enhancing high bio-efficacy fortified in quality. The composition provides an alternative treatment option for subjects suffering from neurological disorders, anxiety, and/or management of related complications without any side effects (AmanchiBala et al., 2021). Mohanty et al. isolated an anticonvulsant drug from Cucurbita maxima and tested it in a convulsion-based animal assay. The pre-treatment with this water–alcohol extract was given biweekly and later exposed to induced electroshock seizures at optimized conditions, and it proved to be effective for electroshock-induced convulsions in rats (Kumar and Nagnath, 2021). Kodimule formulated a composition containing chlorogenic acid and sunflower seed extract in AD (Kodimule, 2021). Palkar and Prasad formulated a synergistic mixture of celery-based extract and various pharmaceutical excipients in brain stroke in different ratios (1:0.1 to 1:5) (Palkar and Prasad, 2021). Vaijanath et al. formulated a Wedelolactone Nasal Formulation. This formulation is made for the nasal drug delivery system to achieve its brain bioavailability for treating or preventing seizures or epilepsy (Vaijnath and Suraj, 2019). Chaudhary et al. formulated a water-soluble extract of Alpinia galanga for improving mental alertness and sustaining attention in humans (Chaudhary et al., 2021).

9 Clinical research

Recently, clinical trial reports manifested that mild-to-moderate dementia patients have been cured by employing naturally originated therapeutics (Yiannopoulou and Papageorgiou, 2013). Both studies including clinical trials for test scores and randomized trial for 30 weeks placebo study, were restricted due to resulting hepatotoxicity (Alfirevic et al., 2007). Berberine, another phytoconstituent, displayed symptoms including constipation, diarrhea, bloating, and stomach pain in human subjects with type 2 diabetes (Yin et al., 2008). In a short-term study based on resveratrol, its repeated dose revealed no major adverse effects, but nearly 13% of the individuals had a frontal headache as a side effect (Shaito et al., 2020). In another phase III trial, cholinesterase inhibitors, including galantamine, donepezil, and rivastigmine, were observed to have a lesser memory-enhancing effect, and side effects, including vomiting, nausea, diarrhea, sleeplessness, muscular spasm, loss of fatigue, and loss of hunger, were observed in severe AD subjects (https://clinicaltrials.gov/ct2/show/NCT02035982). In recent report findings, the investigated anti-AD drugs have been excluded based on approximately 200 clinical trials because of inefficacy and toxicity (Mo et al., 2018). Amyloid blockers have not been marketed yet, although they undergo clinical testing (Huang et al., 2020). Toxicity has been reported, Commercialization of such drugs is constrained by concerns of toxicity, but scientists are discovering a novel pharmacological entity with natural existence (Cummings et al., 2021). Indeed, the multitargeting approach by natural agents observes enhanced safety and potentially cognitive modulating abilities, thus contributing to remarkable efficacious compounds (Sartori and Singewald, 2019). Many clinical observations are available in the form of case reports or preliminary clinical trials, which provide essential clinical leads for the initiation of any serious clinical trial in the related area on the background of experimental studies. Interestingly, Ghodsi et al. designed a randomized, triple-blind, placebo-controlled study and evaluated curcumin in 30 idiopathic PD patients and 30 placebo groups as an add-on therapy at 80 mg/kg dose for 9 months. The movement disorder society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part-III was p = 0.04, exhibiting a significant difference in patient groups, and nausea and vomiting with p = 0.25 and gastroesophageal reflux with p = 0.42 were side effects (Ghodsi et al., 2022b). Recently, Wang et al. examined a systematic and meta-analysis overview of the accessible preclinical data and plausible mechanisms of baicalein based on in vivo PD studies. Twenty different studies were implied, and the data analysis observed that baicalein can enhance neuroprotective action such as instant motor activity (n = 5), pole (n = 2), rotarod (n = 9), apomorphine-induced rotations (n = 4), grid (n = 2), and tremor (n = 2) tests in comparison to control. The study reported multi-signaling pathways, including neurotransmitter modulation, modifying enzyme activity, relieving oxidative stress, blocking protein aggregation, and further restricting apoptosis (Wang et al., 2020). In another retrospective trial, the pharmacological effect of the artisanal oil formulation of cannabidiol was investigated for epilepsy among 108 pediatric populations. The study observed that 39% of patients showed a major decrease in seizures (more than 50%), and 10% showed no seizures. In contrast, 44% patients exhibited a 50% reduction compared to the 33% with only cannabidiol in the group that was observed receiving combination therapy with cannabidiol and clobazam. The overall results exhibited better alertness and enhanced verbal communication in cannabidiol patients in comparison to the cannabidiol and clobazam patient group, which also showed sedation as its side effect (non-statistically significant difference) (Porcari et al., 2018).

There are few and conflicting pharmacological and clinical studies on the effectiveness of traditional Chinese systems and herbal mixtures in AD. Concerns with irreproducibility may result from this incapacity to deal with uncertainty. Consequently, due to their natural occurrence, promising drug delivery to the brain, and lower adverse effects, the complexes of nanoparticles and herbal plants or their constituents called nano-phytomedicine have currently become essential in the progression of novel neuro-therapeutics. Nanotheranostics is a strategy attracting much interest worldwide for the management of neurodegenerative disorders. Nanoformulations are used in management and diagnosis at the same time. Researchers have created a revolutionary nanotheranostic system that reflects the utilization of nanoparticles and expands the potential applications in this field (Bhattacharya et al., 2022). Toward this direction, Noor et al. established curcumin-based intracerebroventricular injection at a sub-diabetogenic dose of streptozotocin for AD. Curcumin ameliorated the behavioral, immunohistochemical, and most of the neurochemical alterations induced by streptozotocin in the hippocampus and cortex portion, thus showing prospects for brain drug delivery. Thuraisingam et al. formulated nanoemulsions containing Centella asiatica crude extract to penetrate the blood–brain barrier using the low-energy emulsification method, showing promising results against epilepsy. Junior et al. compared nanoemulsions of curcumin with free curcumin through an experimental model for PD. The study concluded that curcumin-loaded nanoemulsions and free curcumin enhanced motor impairment decreased lipoperoxidation, modified antioxidant protection, and inhibited the formation of complex I (Ramires Júnior et al., 2021; Noor et al., 2022; Thuraisingam et al., 2022).

10 Conclusion

In summary, medicinal plants constitute a significant reservoir of various bioactive ingredients. The implementation of effective multi-targeted drugs for the treatment and prevention of various diseases, including neurological disorders, may result from ethnopharmacology-focused studies that provide a scientific basis for the effective dose and promising toxicological effects on the local community. The key insight is that natural products may hold enormous therapeutic potential for varied neurological diseases as conventional treatments, including synthetic medications, only aim to relieve symptoms and are completely inadequate because they cannot arrest the evolution of the diseased condition. However, the uncertainties regarding the effectiveness and efficacy of several natural products present a challenge. A lot still needs to be studied, described, and discovered. The chemical modification of natural phytoconstituents and molecular docking of those compounds may improve the potency and efficacy of natural products. Thus, to improve patient safety and ethical treatment, clinicians must frequently investigate the employability of all products, such as conventional, complementary, and alternative. Furthermore, experts should deliberately begin to increase scientific understanding of the efficacy and safety of natural products, underlining the need for fundamental research to enhance scientific understanding of the fundamental biological mechanisms. The best sources of novel therapeutics and active frameworks are still natural products. When synthetic and biological chemists collaborate on these case studies, novel structures with the potential to treat a range of human diseases can be investigated.

11 Future prospectives

Pain associated with neurodevelopmental disorders and neurodegenerative diseases are common, as are conditions which includes Parkinson’s disease (PD), dementia, epilepsy, and neuro infections caused by malnutrition. The pharmacological properties of medicinal plants have been effective in treating various neurological conditions. Although many different types of plants are available globally, only a few have been researched for neurological problems. Therefore, there are several chances for more exploration of botanicals and their bioactive compounds in this field. In recent years, there has been an increase in interest in natural alternative treatments that encourage fast recovery and avoid side effects. The use of natural compounds in alternative and complementary therapies may result in the identification of novel drug lead compounds. The use of natural compounds to treat neurodegenerative illnesses has gradually become a growing industry. In addition to providing a scientific foundation for the ideal dose and potential toxicological effects on the local community, pharmacological studies can aid in the development of even more effective therapeutically multi-targeted natural compounds for the treatment of various neurological disorders.

References

• 1

  Aboulwafa M. M. Youssef F. S. Gad H. A. Altyar A. E. Al-Azizi M. M. Ashour M. L. (2019). A comprehensive insight on the health benefits and phytoconstituents of Camellia sinensis and recent approaches for its quality control. Antioxidants8, 455. 10.3390/antiox8100455

  • CrossRef
  • Google Scholar

• 2

  Abrahams S. Miller H. C. Lombard C. van der Westhuizen F. H. Bardien S. (2021). Curcumin pre-treatment may protect against mitochondrial damage in LRRK2-mutant Parkinson’s disease and healthy control fibroblasts. Biochem. Biophys. Rep.27, 101035. 10.1016/j.bbrep.2021.101035

  • CrossRef
  • Google Scholar

• 3

  Abreu T. M. Corpe F. P. Teles F. B. da ConceiçãoRivanor R. L. de Sousa C. N. da Silva Medeiros I. et al (2022). Lectin isolated from the red marine alga Solieria filiformis (kützing) PW gabrielson: Secondary structure and antidepressant-like effect in mice submitted to the lipopolysaccharide-induced inflammatory model of depression. Algal Res.65, 102715. 10.1016/j.algal.2022.102715

  • CrossRef
  • Google Scholar

• 4

  Abu-Izneid T. Rauf A. Khalil A. A. Olatunde A. Khalid A. Alhumaydhi F. A. et al (2022). Nutritional and health beneficial properties of saffron (Crocus sativus L.): A comprehensive review. Crit. Rev. Food Sci. Nutr.62, 2683–2706. 10.1080/10408398.2020.1857682

  • CrossRef
  • Google Scholar

• 5

  Aditi K. Singh A. Shakarad M. N. Agrawal N. (2022). Management of altered metabolic activity in Drosophila model of Huntington’s disease by curcumin. Exp. Biol. Med.247, 152–164. 10.1177/15353702211046927

  • CrossRef
  • Google Scholar

• 6

  Akbar M. Shabbir A. Rehman K. Akash M. S. H. Shah M. A. (2021). Neuroprotective potential of berberine in modulating Alzheimer’s disease via multiple signaling pathways. J. Food Biochem.45, e13936. 10.1111/jfbc.13936

  • CrossRef
  • Google Scholar

• 7

  Akhlaghi M. Shabanian G. Rafieian-Kopaei M. Parvin N. Saadat M. Akhlaghi M. (2011). Citrus aurantium blossom and preoperative anxiety. Rev. Bras. Anestesiol.61, 702–712. 10.1016/S0034-7094(11)70079-4

  • CrossRef
  • Google Scholar

• 8

  Akhondzadeh S. Naghavi H. R. Vazirian M. Shayeganpour A. Rashidi H. Khani M. (2001). Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J. Clin. Pharm. Ther.26, 363–367. 10.1046/j.1365-2710.2001.00367.x

  • CrossRef
  • Google Scholar

• 9

  Alfirevic A. Mills T. Carr D. Barratt B. J. Jawaid A. Sherwood J. et al (2007). Tacrine-induced liver damage: An analysis of 19 candidate genes. Pharmacogenet. Genomics17, 1091–1100. 10.1097/FPC.0b013e3282f1f12b

  • CrossRef
  • Google Scholar

• 10

  Ali B. H. Bashir A. K. Tanira M. O. Medvedev A. E. Jarrett N. Sandler M. et al (1998). Effect of extract of Rhazya stricta, a traditional medicinal plant, on rat brain tribulin. Pharmacol. Biochem. Behav.59, 671–675. 10.1016/S0091-3057(97)00464-4

  • CrossRef
  • Google Scholar

• 11

  Ali B. H. Bashir A. K. Tanira M. O. (1998). The effect of Rhazya stricta Decne, a traditional medicinal plant, on the forced swimming test in rats. Pharmacol. Biochem. Behav.59, 547–550. 10.1016/S0091-3057(97)00470-X

  • CrossRef
  • Google Scholar

• 12

  Aliakbari F. Mohammad-Beigi H. Rezaei-Ghaleh N. Becker S. Esmatabad F. D. Seyedi H. A. E. et al (2018). The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson’s disease. Nanoscale10, 9174–9185. 10.1039/C8NR00632F

  • CrossRef
  • Google Scholar

• 13

  Álvarez S. A. Rocha-Guzmán N. E. González-Laredo R. F. Gallegos-Infante J. A. Moreno-Jiménez M. R. Bravo-Muñoz M. (2022). Ancestral food sources rich in polyphenols, their metabolism, and the potential influence of gut microbiota in the management of depression and anxiety. J. Agric. Food Chem.70, 944–956. 10.1021/acs.jafc.1c06151

  • CrossRef
  • Google Scholar

• 14

  AmanchiBala S. S. Upadhyayala N. Ganga Mod N. V. (2021). “A synergistic nano polyherbal formulation for Parkinson disorder,”. IN201941028495.

  • Google Scholar

• 15

  Amro M. S. Teoh S. L. Norzana A. G. Srijit D. (2018). The potential role of herbal products in the treatment of Parkinson’s disease. Clin. Ter.169, 23–33. 10.7417/T.2018.2050

  • CrossRef
  • Google Scholar

• 16

  Anakor E. Milla V. Connolly O. Martinat C. Pradat P. F. Dumonceaux J. et al (2022). The neurotoxicity of vesicles secreted by ALS patient myotubes is specific to exosome-like and not larger subtypes. Cells11, 845. 10.3390/cells11050845

  • CrossRef
  • Google Scholar

• 17

  Andrade C. Aswath A. Chaturvedi S. K. Srinivasa M. Raguram R. (2000). A double-blind, placebo-controlled evaluation of the anxiolytic efficacy ff an ethanolic extract of Withania somnifera. Indian J. Psychiatry42, 295–301.

  • Google Scholar

• 18

  Andreatini R. Leite J. (1994). Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur. J. Pharmacol.260, 233–235. 10.1016/0014-2999(94)90342-5

  • CrossRef
  • Google Scholar

• 19

  Andreatini R. Sartori V. A. Seabra M. L. Leite J. R. (2002). Effect of valepotriates (valerian extract) in generalized anxiety disorder: A randomized placebo-controlled pilot study. Phytother. Res.16, 650–654. 10.1002/ptr.1027

  • CrossRef
  • Google Scholar

• 20

  Angelucci F. Cechova K. Valis M. Kuca K. Zhang B. Hort J. (2019). MicroRNAs in alzheimer’s disease: Diagnostic markers or therapeutic agents?Front. Pharmacol.10, 665. 10.3389/fphar.2019.00665

  • CrossRef
  • Google Scholar

• 21

  Ankireddy S. R. Kim J. (2015). Selective detection of dopamine in the presence of ascorbic acid via fluorescence quenching of InP/ZnS quantum dots. Int. J. Nanomedicine10, 113–119. 10.2147/IJN.S88388

  • CrossRef
  • Google Scholar

• 22

  Anuradha H. Srikumar B. N. Rao S. Lakshmana M. (2008). Euphorbia hirta reverses chronic stress-induced anxiety and mediates its action through the GABAA receptor benzodiazepine receptor-Cl− channel complex. J. Neural Transm.115, 35–42. 10.1007/s00702-007-0821-6

  • CrossRef
  • Google Scholar

• 23

  Araújo J. R. de Melo J. D. Damasceno M. D. Santos S. A. Vieira-Neto A. E. Lobo M. D. et al (2018). Neuropharmacological characterization of frutalin in mice: Evidence of an antidepressant-like effect mediated by the NMDA receptor/NO/cGMP pathway. Int. J. Biol. Macromol.112, 548–554. 10.1016/j.ijbiomac.2018.01.180

  • CrossRef
  • Google Scholar

• 24

  Arnold S., J. Dugger B. N. Beach T. G. (2013). TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: Correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol.126, 51–57. 10.1007/s00401-013-1110-0

  • CrossRef
  • Google Scholar

• 25

  Aslanargun P. Cuvas O. Dikmen B. Aslan E. Yuksel M. U. (2012). Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J. Anesth.26, 39–44. 10.1007/s00540-011-1265-6

  • CrossRef
  • Google Scholar

• 26

  Assad R. Reshi Z. A. Mir S. H. Rashid I. Shouche Y. Dhotre D. (2021). Bioprospecting appraisal of Himalayan pindrow fir for pharmacological applications. Phytomedicine Academic Press, 461–482. 10.1016/B978-0-12-824109-7.00003-0

  • CrossRef
  • Google Scholar

• 27

  Awad R. Levac D. Cybulska P. Merali Z. Trudeau V. L. Arnason J. T. (2007). Effects of traditionally used anxiolytic botanicals on enzymes of the γ-aminobutyric acid (GABA) system. Can. J. Physiol. Pharmacol.85, 933–942. 10.1139/Y07-083

  • CrossRef
  • Google Scholar

• 28

  Ayaz M. Sadiq A. Junaid M. Ullah F. Ovais M. Ullah I. et al (2019). Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders. Front. Aging Neurosci.11, 155. 10.3389/fnagi.2019.00155

  • CrossRef
  • Google Scholar

• 29

  Bakhtiari M. Panahi Y. Ameli J. Darvishi B. (2017). Protective effects of flavonoids against Alzheimer’s disease-related neural dysfunctions. Biomed. Pharmacother.93, 218–229. 10.1016/j.biopha.2017.06.010

  • CrossRef
  • Google Scholar

• 30

  Ball N. Teo W. P. Chandra S. Chapman J. (2019). Parkinson's disease and the environment. Front. Neurol.218, 218. 10.3389/fneur.2019.00218

  • CrossRef
  • Google Scholar

• 31

  Banerjee C. Nandy S. Chakraborty J. Kumar D. (2022). Myricitrin–a flavonoid isolated from the Indian olive tree (Elaeocarpus floribundus)–inhibits monoamine oxidase in the brain and elevates striatal dopamine levels: Therapeutic implications against Parkinson's disease. Food Funct.13, 6545–6559. 10.1039/D2FO00734G

  • CrossRef
  • Google Scholar

• 32

  Baretta I. P. Felizardo R. A. Bimbato V. F. dos Santos M. G. Kassuya C. A. Junior A. G. et al (2012). Anxiolytic-like effects of acute and chronic treatment with Achillea millefolium L. extract. J. Ethnopharmacol.140, 46–54. 10.1016/j.jep.2011.11.047

  • CrossRef
  • Google Scholar

• 33

  Baum L. Lam C. W. K. Cheung S. K.-K. Kwok T. Lui V. Tsoh J. et al (2008). Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol.28, 110–113. 10.1097/jcp.0b013e318160862c

  • CrossRef
  • Google Scholar

• 34

  Bazyar H. Hosseini S. A. Saradar S. Mombaini D. Allivand M. Labibzadeh M. et al (2021). Effects of epigallocatechin-3-gallate of Camellia sinensis leaves on blood pressure, lipid profile, atherogenic index of plasma and some inflammatory and antioxidant markers in type 2 diabetes mellitus patients: A clinical trial. J. Complement. Integr. Med.18, 405–411. 10.1515/jcim-2020-0090

  • CrossRef
  • Google Scholar

• 35

  Benke D. Barberis A. Kopp S. Altmann K. H. Schubiger M. Vogt K. E. et al (2009). GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology56, 174–181. 10.1016/j.neuropharm.2008.06.013

  • CrossRef
  • Google Scholar

• 36

  Bergamaschi M. M. Queiroz R. H. Chagas M. H. De Oliveira D. C. De Martinis B. S. Kapczinski F. et al (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology36, 1219–1226. 10.1038/npp.2011.6

  • CrossRef
  • Google Scholar

• 37

  Bhattacharya T. Soares G. A. Chopra H. Rahman M. M. Hasan Z. Swain S. S. et al (2022). Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. Materials15, 804. 10.3390/ma15030804

  • CrossRef
  • Google Scholar

• 38

  Bonokwane M. B. Lekhooa M. Struwig M. Aremu A. O. (2022). Antidepressant effects of south african plants: An appraisal of ethnobotanical surveys, ethnopharmacological and phytochemical studies. Front. Pharmacol.13, 895286. 10.3389/fphar.2022.895286

  • CrossRef
  • Google Scholar

• 39

  Brochard V. Combadiere B. Prigent A. Laouar Y. Perrin A. Beray-Berthat V. et al (2009). Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest.119, 182–192. 10.1172/JCI36470

  • CrossRef
  • Google Scholar

• 40

  Butterweck V. Nishibe S. Sasaki T. Uchida M. (2001). Antidepressant effects of Apocynum venetum leaves in a forced swimming test. Biol. Pharm. Bull.24, 848–851. 10.1248/bpb.24.848

  • CrossRef
  • Google Scholar

• 41

  Cáceres Guido P. Riva N. Caraballo R. Reyes G. Huaman M. Gutierrez R. et al (2021). Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy. Epilepsia62, e7–e12. 10.1111/epi.16781

  • CrossRef
  • Google Scholar

• 42

  Calabrese C. Gregory W. L. Leo M. Kraemer D. Bone K. Oken B. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J. Altern. Complement. Med.14, 707–713. 10.1089/acm.2008.0018

  • CrossRef
  • Google Scholar

• 43

  Callahan B. L. Ramakrishnan N. Shammi P. Bierstone D. Taylor R. Ozzoude M. et al (2022). Cognitive and neuroimaging profiles of older adults with attention deficit/hyperactivity disorder presenting to a memory clinic. J. Atten. Disord.26, 1118–1129. 10.1177/10870547211060546

  • CrossRef
  • Google Scholar

• 44

  Campos A. C. Guimarães F. S. (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology199, 223–230. 10.1007/s00213-008-1168-x

  • CrossRef
  • Google Scholar

• 45

  Chainoglou E. Hadjipavlou-Litina D. (2020). Curcumin in health and diseases: Alzheimer’s disease and curcumin analogues, derivatives, and hybrids. Int. J. Mol. Sci.21, 1975. 10.3390/ijms21061975

  • CrossRef
  • Google Scholar

• 46

  Chandran P. Chandramohan K. Iyer K. Michael F. M. Seppan P. Venkatachalam S. (2022). Beneficial effects of ethanolic extract of the medicinal herb Mucuna pruriens against oxidative stress and inflammation might be limited in contusive spinal cord injury. Biomed. Pharmacol. J.15, 235–248. 10.13005/bpj/2359

  • CrossRef
  • Google Scholar

• 47

  Charles P. D. Ambigapathy G. Geraldine P. Akbarsha M. A. Rajan K. E. (2011). Bacopa monniera leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: Implications in memory formation. J. Ethnopharmacol.134, 55–61. 10.1016/j.jep.2010.11.045

  • CrossRef
  • Google Scholar

• 48

  Chaudhary J. Chaudhary L. Dighe S. Srivastva S. (2021). “Formulation containing an extract of Alpinia galanga, a process for the preparation thereof, and uses thereof,”. US20210205400A1.

  • Google Scholar

• 49

  Chen G. F. Xu T. H. Yan Y. Zhou Y. R. Jiang Y. Melcher K. et al (2017). Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin.38, 1205–1235. 10.1038/aps.2017.28

  • CrossRef
  • Google Scholar

• 50

  Chen Y. Chen Y. Liang Y. Chen H. Ji X. Huang M. (2020). Berberine mitigates cognitive decline in an Alzheimer’s disease mouse model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed. Pharmacother.121, 109670. 10.1016/j.biopha.2019.109670

  • CrossRef
  • Google Scholar

• 51

  Cheng M. C. Li C. Y. Ko H. C. Ko F. N. Lin Y. L. Wu T. S. (2006). Antidepressant principles of the roots of Polygala tenuifolia. J. Nat. Prod.69, 1305–1309. 10.1021/np060207r

  • CrossRef
  • Google Scholar

• 52

  Chinraj V. Raman S. (2022). Neuroprotection by resveratrol: A review on brain delivery strategies for alzheimer’s and Parkinson’s disease. J. Appl. Pharm. Sci.12, 001–017. 10.7324/JAPS.2022.120701

  • CrossRef
  • Google Scholar

• 53

  Ciccone L. Vandooren J. Nencetti S. Orlandini E. (2021). Natural marine and terrestrial compounds as modulators of matrix metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer's disease. Pharm. (Basel, Switz.14, 86. 10.3390/ph14020086

  • CrossRef
  • Google Scholar

• 54

  Cragg G. M. Grothaus P. G. Newman D. J. (2009). Impact of natural products on developing new anti-cancer agents. Chem. Rev.109, 3012–3043. 10.1021/cr900019j

  • CrossRef
  • Google Scholar

• 55

  Cragg G. M. Newman D. J. (2002). Chemical diversity: A function of biodiversity. Trends Pharmacol. Sci.23, 404–405. 10.1016/s0165-6147(02)02099-0

  • CrossRef
  • Google Scholar

• 56

  Cui C. Yang M. Yao Z. Cao B. Luo Z. Xu Y. et al (1995). [Antidepressant active constituents in the roots of Morinda officinalis How]. China J. Chin. Mater. Medica.20, 36–63.

  • Google Scholar

• 57

  Cummings J. Lee G. Zhong K. Fonseca J. Taghva K. (2021). Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement.7, e12179. 10.1002/trc2.12179

  • CrossRef
  • Google Scholar

• 58

  Dang H. Chen Y. Liu X. Wang Q. Wang L. Jia W. et al (2009). Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry33, 1417–1424. 10.1016/j.pnpbp.2009.07.020

  • CrossRef
  • Google Scholar

• 59

  Devinsky O. Cilio M. R. Cross H. Fernandez-Ruiz J. French J. Hill C. et al (2014). Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia55, 791–802. 10.1111/epi.12631

  • CrossRef
  • Google Scholar

• 60

  Dhingra D. Goyal P. K. (2008). Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant-like activity of Tinospora cordifolia in mice. Indian J. Pharm. Sci.70, 761–767. 10.4103/0250-474X.49118

  • CrossRef
  • Google Scholar

• 61

  Dhingra D. Joshi P. (2012). Antidepressant-like activity of Benincasa hispida fruits in mice: Possible involvement of monoaminergic and GABAergic systems. J. Pharmacol. Pharmacother.3, 60–62. 10.4103/0976-500X.92521

  • CrossRef
  • Google Scholar

• 62

  Dhingra D. Joshi P. Gupta A. Chhillar R. (2012). Possible involvement of monoaminergic neurotransmission in antidepressant-like activity of Emblica officinalis fruits in mice. CNS Neurosci. Ther.18, 419–425. 10.1111/j.1755-5949.2011.00256.x

  • CrossRef
  • Google Scholar

• 63

  Dhingra D. Kumar V. (2007). Pharmacological evaluation for antidepressant-like activity of Asparagus racemosus Wild. in mice. Pharmacologyonline3, 133–152. 10.1007/s40495-022-00300-0

  • CrossRef
  • Google Scholar

• 64

  Dhingra D. Sharma A. (2006). Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Prog. Neuropsychopharmacol. Biol. Psychiatry30, 449–454. 10.1016/j.pnpbp.2005.11.019

  • CrossRef
  • Google Scholar

• 65

  Domenighetti C. Douillard V. Sugier P. E. Sreelatha A. A. Schulte C. Grover S. et al (2022). The interaction between HLA-DRB1 and smoking in Parkinson's disease revisited. Mov. Disord.37, 1929–1937. 10.1002/mds.29133

  • CrossRef
  • Google Scholar

• 66

  Duan Q. Jing Z. Zou X. Wang Y. Yang K. Zhang T. et al (2020). Spiking neurons with spatiotemporal dynamics and gain modulation for monolithically integrated memristive neural networks. Nat. Commun.11, 1–13. 10.1038/s41467-020-17215-3

  • CrossRef
  • Google Scholar

• 67

  Duan Z. Li A. Gong H. Li X. (2020). A whole-brain map of long-range inputs to GABAergic interneurons in the mouse caudal forelimb area. Neurosci. Bull.36, 493–505. 10.1007/s12264-019-00458-6

  • CrossRef
  • Google Scholar

• 68

  Duman R. S. Voleti B. (2012). Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents. Trends Neurosci.35, 47–56. 10.1016/j.tins.2011.11.004

  • CrossRef
  • Google Scholar

• 69

  Ekor M. (2014). The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol.4, 177. 10.3389/fphar.2013.00177

  • CrossRef
  • Google Scholar

• 70

  Esselun C. Dieter F. Sus N. Frank J. Eckert G. P. (2022). Walnut oil reduces Aβ levels and increases neurite length in a cellular model of early alzheimer disease. Nutrients14, 1694. 10.3390/nu14091694

  • CrossRef
  • Google Scholar

• 71

  Ettehadi H. Mojabi S. N. Ranjbaran M. Shams J. Sahraei H. Hedayati M. et al (2013). Aqueous extract of saffron (Crocus sativus) increases brain dopamine and glutamate concentrations in rats. J. Behav. Brain Sci.3, 315–319. 10.4236/jbbs.2013.33031

  • CrossRef
  • Google Scholar

• 72

  Fakhri S. Iranpanah A. Gravandi M. M. Moradi S. Z. Ranjbari M. Majnooni M. B. et al (2021). Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration. Phytomedicine.91, 153664. 10.1016/j.phymed.2021.153664

  • CrossRef
  • Google Scholar

• 73

  Fan Z. Z. Zhao W. H. Guo J. Cheng R. F. Zhao J. Y. Yang W. D. et al (2012). Antidepressant activities of flavonoids from Glycyrrhiza uralensis and its neurogenesis protective effect in rats. Yao xuexue bao=Acta Pharm.Sin. B47, 1612–1617. 23460966.

  • Google Scholar

• 74

  Fantacuzzi M. Amoroso R. Carradori S. De Filippis B. (2022). Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy. Eur. J. Med. Chem.233, 114242. 10.1016/j.ejmech.2022.114242

  • CrossRef
  • Google Scholar

• 75

  Fehske C. J. Leuner K. Müller W. E. (2009). Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol. Res.60, 68–73. 10.1016/j.phrs.2009.02.012

  • CrossRef
  • Google Scholar

• 76

  Fields C. Bischof J. Levin M. (2020). Morphological coordination: A common ancestral function unifying neural and non-neural signaling. Physiology35, 16–30. 10.1152/physiol.00027.2019

  • CrossRef
  • Google Scholar

• 77

  Fields C. R. Bengoa-Vergniory N. Wade-Martins R. (2019). Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front. Mol. Neurosci.12, 299. 10.3389/fnmol.2019.00299

  • CrossRef
  • Google Scholar

• 78

  Fuloria S. Yusri M. A. Sekar M. Gan S. H. Rani N. N. Lum P. T. et al (2022). Genistein: A potential natural lead molecule for new drug design and development for treating memory impairment. Molecules27, 265. 10.3390/molecules27010265

  • CrossRef
  • Google Scholar

• 79

  Gadaga L. L. Tagwireyi D. Dzangare J. Nhachi C. F. (2011). Acute oral toxicity and neurobehavioural toxicological effects of hydroethanolic extract of Boophone disticha in rats. Hum. Exp. Toxicol.30, 972–980. 10.1177/0960327110384524

  • CrossRef
  • Google Scholar

• 80

  Gao H. Lei X. Ye S. Ye T. Hua R. Wang G. et al (2022). Genistein attenuates memory impairment in Alzheimer's disease via ERS-mediated apoptotic pathway in vivo and in vitro. J. Nutr. Biochem.109, 109118. 10.1016/j.jnutbio.2022.109118

  • CrossRef
  • Google Scholar

• 81

  Gaur V. Bodhankar S. L. Mohan V. Thakurdesai P. (2012). Antidepressant-like effect of 4-hydroxyisoleucine from Trigonella foenum graecum L. seeds in mice. Biomed. Aging Pathology2, 121–125. 10.1016/j.biomag.2012.07.002

  • CrossRef
  • Google Scholar

• 82

  George J. Nihal M. Singh C. K. Ahmad N. (2019). 4′-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming. Mol. Carcinog.58, 1876–1885. 10.1002/mc.23080

  • CrossRef
  • Google Scholar

• 83

  Ghadrdoost B. Vafaei A. A. Rashidy-Pour A. Hajisoltani R. Bandegi A. R. Motamedi Fhaghighi S. et al (2011). Protective effects of saffron extract and its active constituent crocin against oxidative stress and spatial learning and memory deficits induced by chronic stress in rats. Eur. J. Pharmacol.667, 222–229. 10.1016/j.ejphar.2011.05.012

  • CrossRef
  • Google Scholar

• 84

  Ghodsi H. Rahimi H. R. Aghili S. M. Saberi A. Shoeibi A. (2022). Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: A pilot randomized, triple-blind, placebo-controlled trial. Clin. Neurol. Neurosurg.218, 107300. 10.1016/j.clineuro.2022.107300

  • CrossRef
  • Google Scholar

• 85

  Ghodsi H. Rahimi H. R. Aghili S. M. Saberi A. Shoeibi A. (2022). Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: A pilot randomized, triple-blind, placebo-controlled trial. Clin. Neurol. Neurosurg.18, 107300. 10.1016/j.clineuro.2022.107300

  • CrossRef
  • Google Scholar

• 86

  Ginwala R. Bhavsar R. Chigbu D. G. I. Jain P. Khan Z. K. (2019). Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants8, 35. 10.3390/antiox8020035

  • CrossRef
  • Google Scholar

• 87

  Girish C. Raj V. Arya J. Balakrishnan S. (2012). Evidence for the involvement of the monoaminergic system, but not the opioid system in the antidepressant-like activity of ellagic acid in mice. Eur. J. Pharmacol.682, 118–125. 10.1016/j.ejphar.2012.02.034

  • CrossRef
  • Google Scholar

• 88

  Gold C. A. Budson A. E. (2008). Memory loss in alzheimer’s disease: Implications for development of therapeutics. Expert Rev. Neurother.8, 1879–1891. 10.1586/14737175.8.12.1879

  • CrossRef
  • Google Scholar

• 89

  Goldenberg M. M. (2010). Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. P Trans.35, 392–415. 20689626.

  • Google Scholar

• 90

  Gonzalez J. Jurado-Coronel J. C. Avila M. F. Sabogal A. Capani F. Barreto G. E. (2015). NMDARs in neurological diseases: A potential therapeutic target. Int. J. Neurosci.125, 315–327. 10.3109/00207454.2014.940941

  • CrossRef
  • Google Scholar

• 91

  Gorina-Careta N. Kurkela J. L. Hämäläinen J. Astikainen P. Escera C. (2021). Neural generators of the frequency-following response elicited to stimuli of low and high frequency: A magnetoencephalographic (MEG) study. Neuroimage231, 117866. 10.1016/j.neuroimage.2021.117866

  • CrossRef
  • Google Scholar

• 92

  Gouda N. A. Elkamhawy A. Cho J. (2022). Emerging therapeutic strategies for Parkinson’s disease and future prospects: A 2021 update. Biomedicines10, 371. 10.3390/biomedicines10020371

  • CrossRef
  • Google Scholar

• 93

  Gray R. A. Whalley B. J. (2020). The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord.22, 10–15. 10.1684/epd.2020.1135

  • CrossRef
  • Google Scholar

• 94

  Greenfield D. P. (2022). “Basic principles of pharmacology, psychopharmacology, and psychopharmacotherapy,” in Psychopharmacology for NonpsychiatristsSpringer (Cham, 9–25. 10.1007/978-3-030-82507-2_2

  • CrossRef
  • Google Scholar

• 95

  Grewal A. K. Singh T. G. Sharma D. Sharma V. Singh M. Rahman M. H. et al (2021). Mechanistic insights and perspectives involved in neuroprotective action of quercetin. Biomed. Pharmacother.140, 111729. 10.1016/j.biopha.2021.111729

  • CrossRef
  • Google Scholar

• 96

  Grundmann O. Nakajima J. I. Seo S. Butterweck V. (2007). Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test. J. Ethnopharmacol.110, 406–411. 10.1016/j.jep.2006.09.035

  • CrossRef
  • Google Scholar

• 97

  Guo P. Benito Ballesteros A. Yeung S. P. Liu R. Saha A. Curtis L. et al (2022). Covcog 2: Cognitive and memory deficits in long COVID: A second publication from the Covid and cognition study. Front. Aging Neurosci.14, 804937. 10.3389/fnagi.2022.804937

  • CrossRef
  • Google Scholar

• 98

  Gupta S. C. Patchva S. Aggarwal B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J.15, 195–218. 10.1208/s12248-012-9432-8

  • CrossRef
  • Google Scholar

• 99

  Hadrich F. Chamkha M. Sayadi S. (2022). Protective effect of olive leaves phenolic compounds against neurodegenerative disorders: Promising alternative for alzheimer and Parkinson diseases modulation. Food Chem. Toxicol.159, 112752. 10.1016/j.fct.2021.112752

  • CrossRef
  • Google Scholar

• 100

  Hafiz Z. Z. Amin M. A. Johari James R. M. Teh L. K. Salleh M. Z. Adenan M. I. (2020). Inhibitory effects of raw-extract Centella asiatica (RECA) on acetylcholinesterase, inflammations, and oxidative stress activities via in vitro and in vivo. Molecules25, 892. 10.3390/molecules25040892

  • CrossRef
  • Google Scholar

• 101

  Halperin J. M. Healey D. M. (2011). The influences of environmental enrichment, cognitive enhancement, and physical exercise on brain development: Can we alter the developmental trajectory of ADHD?Neurosci. Biobehav. Rev.35, 621–634. 10.1016/j.neubiorev.2010.07.006

  • CrossRef
  • Google Scholar

• 102

  Hampel H. Hardy J. Blennow K. Chen C. Perry G. Kim S. H. et al (2021). The amyloid-β pathway in Alzheimer’s disease. Mol. Psychiatry26, 5481–5503. 10.1038/s41380-021-01249-0

  • CrossRef
  • Google Scholar

• 103

  Hannan M. A. Dash R. Habib M. Al A. Sohag A. Moon I.-S. (2020). Mechanistic insights into the curcumin-mediated neuroprotection in Alzheimer’s disease: An integrated system pharmacology and molecular simulation study . 10.20944/preprints202001.0109.v1Preprints2020010109

  • CrossRef
  • Google Scholar

• 104

  Hardy J. Selkoe D. J. (2002). The amyloid hypothesis of alzheimer's disease: Progress and problems on the road to therapeutics. Science297, 353–356. 10.1126/science.1072994

  • CrossRef
  • Google Scholar

• 105

  Haron S. Kilmister E. J. Davis P. F. Stylli S. S. Mantamadiotis T. Kaye A. H. et al (2021). The renin-angiotensin system in central nervous system tumors and degenerative diseases. Front. Biosci.26, 628–642. 10.52586/4972

  • CrossRef
  • Google Scholar

• 106

  Hashemi P. Fahanik Babaei J. Vazifekhah S. Nikbakht F. (2019). Evaluation of the neuroprotective, anticonvulsant, and cognition-improvement effects of apigenin in temporal lobe epilepsy: Involvement of the mitochondrial apoptotic pathway. Iran. J. Basic Med. Sci.22, 752–758. 10.22038/ijbms.2019.33892.8064

  • CrossRef
  • Google Scholar

• 107

  Heiney S. A. Wojaczynski G. J. Medina J. F. (2021). Action-based organization of a cerebellar module specialized for predictive control of multiple body parts. Neuron109, 2981–2994.e5. 10.1016/j.neuron.2021.08.017

  • CrossRef
  • Google Scholar

• 108

  Hellion-Ibarrola M. C. Ibarrola D. A. Montalbetti Y. Kennedy M. L. Heinichen O. Campuzano M. et al (2006). The anxiolytic-like effects of Aloysia polystachya (Griseb.) Moldenke (Verbenaceae) in mice. J. Ethnopharmacol.105, 400–408. 10.1016/j.jep.2005.11.013

  • CrossRef
  • Google Scholar

• 109

  Herrera-Arellano A. Jiménez-Ferrer E. Zamilpa A. Morales-Valdéz M. García-Valencia C. E. Tortoriello J. (2007). Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med.73, 713–717. 10.1055/s-2007-981539

  • CrossRef
  • Google Scholar

• 110

  Herrera-Arellano A. Jiménez-Ferrer J. E. Zamilpa A. García-Alonso G. Herrera-Alvarez S. Tortoriello J. (2012). Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial. Planta Med.78, 1529–1535. 10.1055/s-0032-1315110

  • CrossRef
  • Google Scholar

• 111

  Herrera-Ruiz M. González-Cortazar M. Jiménez-Ferrer E. Zamilpa A. Alvarez L. Ramírez G. et al (2006). Anxiolytic effect of natural galphimines from Galphimia glauca and their chemical derivatives. J. Nat. Prod.69, 59–61. 10.1021/np050305x

  • CrossRef
  • Google Scholar

• 112

  Herrera-Ruiz M. Jiménez-Ferrer J. E. De Lima T. C. Avilés-Montes D. Pérez-García D. González-Cortazar M. et al (2006). Anxiolytic and antidepressant-like activity of a standardized extract from Galphimia glauca. Phytomedicine13, 23–28. 10.1016/j.phymed.2005.03.003

  • CrossRef
  • Google Scholar

• 113

  Hewlings S. J. Kalman D. S. (2017). Curcumin: A review of its effects on human health. Foods (Basel, Switz.6, 92. 10.3390/foods6100092

  • CrossRef
  • Google Scholar

• 114

  Hor J. H. Soh E. S. Tan L. Y. Lim V. J. Santosa M. M. Ho B. X. et al (2018). Cell cycle inhibitors protect motor neurons in an organoid model of spinal muscular atrophy. Cell Death Dis.9, 1100–1102. 10.1038/s41419-018-1081-0

  • CrossRef
  • Google Scholar

• 115

  Hosseinzadeh H. Karimi G. Niapoor M. (2003). Antidepressant effect of Crocus sativus L. stigma extracts and their constituents, crocin and safranal, in mice. Acta Hortic.650, 435–445. 10.17660/ActaHortic.2004.650.54

  • CrossRef
  • Google Scholar

• 116

  Hosseinzadeh H. Noraei N. B. (2009). Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mice. Phytother. Res.23, 768–774. 10.1002/ptr.2597

  • CrossRef
  • Google Scholar

• 117

  Hosseinzadeh H. Sadeghnia H. R. (2007). Protective effect of safranal on pentylenetetrazol-induced seizures in the rat: Involvement of GABAergic and opioids systems. Phytomedicine14, 256–262. 10.1016/j.phymed.2006.03.007

  • CrossRef
  • Google Scholar

• 118

  Hu Y. Liu P. Guo D. H. Rahman K. Wang D. X. Xie T. T. (2010). Antidepressant effects of the extract YZ-50 from Polygala tenuifolia in chronic mild stress treated rats and its possible mechanisms. Pharm. Biol.48, 794–800. 10.3109/13880200903280034

  • CrossRef
  • Google Scholar

• 119

  Huang L.-K. Chao S.-P. Hu C.-J. (2020). Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci.27 (1), 18. 10.1186/s12929-019-0609-7

  • CrossRef
  • Google Scholar

• 120

  Huang X.-T. Qian Z.-M. He X. Gong Q. Wu K.-C. Jiang L.-R. et al (2014). Reducing iron in the brain: A novel pharmacologic mechanism of huperzine A in the treatment of alzheimer's disease. Neurobiol. Aging35, 1045–1054. 10.1016/j.neurobiolaging.2013.11.004

  • CrossRef
  • Google Scholar

• 121

  Husain M. A. Laurent B. Plourde M. (2021). APOE and alzheimer’s disease: From lipid transport to physiopathology and therapeutics. Front. Neurosci.15, 630502. 10.3389/fnins.2021.630502

  • CrossRef
  • Google Scholar

• 122

  Ibrahim M. M. Gabr M. T. (2019). Multitarget therapeutic strategies for alzheimer’s disease. Neural Regen. Res.14, 437–440. 10.4103/1673-5374.245463

  • CrossRef
  • Google Scholar

• 123

  Ikawa M. Okazawa H. Yoneda M. (2021). Molecular imaging for mitochondrial metabolism and oxidative stress in mitochondrial diseases and neurodegenerative disorders. Biochim. Biophys. Acta. Gen. Subj.1865, 129832. 10.1016/j.bbagen.2020.129832

  • CrossRef
  • Google Scholar

• 124

  Ion D. Niculescu A. G. Păduraru D. N. Andronic O. Mușat F. Grumezescu A. M. et al (2021). An up-to-date review of natural nanoparticles for cancer management. Pharmaceutics14, 18. 10.3390/pharmaceutics14010018

  • CrossRef
  • Google Scholar

• 125

  Islam F. Bepary S. Nafady M. H. Islam M. Emran T. B. Sultana S. et al (2022). Polyphenols targeting oxidative stress in spinal cord injury: Current status and future vision. Oxid. Med. Cell. Longev.2022, 8741787. 10.1155/2022/8741787

  • CrossRef
  • Google Scholar

• 126

  Ito N. Yabe T. Gamo Y. Nagai T. Oikawa T. Yamada H. et al (2008). Rosmarinic acid from PerillaeHerba produces an antidepressant-like effect in mice through cell proliferation in the hippocampus. Biol. Pharm. Bull.31, 1376–1380. 10.1248/bpb.31.1376

  • CrossRef
  • Google Scholar

• 127

  Jabir N. R. Khan F. R. Tabrez S. (2018). Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of alzheimer’s disease. CNS Neurosci. Ther.24, 753–762. 10.1111/cns.12971

  • CrossRef
  • Google Scholar

• 128

  Jamwal S. Blackburn J. K. Elsworth J. D. (2021). PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol. Ther.219, 107705. 10.1016/j.pharmthera.2020.107705

  • CrossRef
  • Google Scholar

• 129

  Jankovic J. Sherer T. (2014). The future of research in Parkinson disease. JAMA Neurol.71, 1351–1352. https://doi.org/10.1001/jamaneurol.2014.1717.

  • Google Scholar

• 130

  Jankowska-Kieltyka M. Roman A. Nalepa I. (2021). The air we breathe: Air pollution as a prevalent proinflammatory stimulus contributing to neurodegeneration. Front. Cell. Neurosci.15, 647643. 10.3389/fncel.2021.647643

  • CrossRef
  • Google Scholar

• 131

  Javan Gholiloo M. Yarnia M. Ghorttapeh A. H. Farahvash F. Daneshian A. M. (2019). Evaluating effects of drought stress and bio-fertilizer on quantitative and qualitative traits of valerian (Valeriana officinalis L.)J. Plant Nutr.42, 1417–1429. 10.1080/01904167.2019.1628972

  • CrossRef
  • Google Scholar

• 132

  Jensen N. J. Wodschow H. Z. Nilsson M. Rungby J. (2020). Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int. J. Mol. Sci.21, 8767. 10.3390/ijms21228767

  • CrossRef
  • Google Scholar

• 133

  Jeong K. Shin Y. C. Park S. Park J. S. Kim N. Um J. Y. et al (2011). Ethanol extract of Scutellaria baicalensis Georgi prevents oxidative damage and neuroinflammation and memorial impairments in artificial senescense mice. J. Biomed. Sci.18, 14. 10.1186/1423-0127-18-14

  • CrossRef
  • Google Scholar

• 134

  Jia Y. Wang N. Liu X. (2017). Resveratrol and amyloid-beta: Mechanistic insights. Nutrients9, 1122. 10.3390/nu9101122

  • CrossRef
  • Google Scholar

• 135

  Jiang N. Wang H. Li C. Zeng G. Lv J. Wang Q. et al (2021). The antidepressant-like effects of the water extract of Panax ginseng and Polygala tenuifolia are mediated via the BDNF-TrkB signaling pathway and neurogenesis in the hippocampus. J. Ethnopharmacol.267, 113625. 10.1016/j.jep.2020.113625

  • CrossRef
  • Google Scholar

• 136

  Jiménez-Ferrer E. Herrera-Ruiz M. Ramírez-García R. Herrera-Arellano A. Tortoriello J. (2011). Interaction of the natural anxiolytic Galphimine-B with serotonergic drugs on dorsal hippocampus in rats. J. Ethnopharmacol.137, 724–729. 10.1016/j.jep.2011.06.029

  • CrossRef
  • Google Scholar

• 137

  Jin T. Zhang Y. Benson O. A. Zhang J. Fan R. Zhang Y. et al (2022). Curcumin can improve Parkinson's disease via activating BDNF/PI3k/Akt signaling pathways. Food Chem. Toxicol.113091, 113091. 10.1016/j.fct.2022.113091

  • CrossRef
  • Google Scholar

• 138

  Jin Z. L. Gao N. Zhou D. Chi M. G. Yang X. M. Xu J. P. (2012). The extracts of fructus akebiae, a preparation containing 90% of the active ingredient hederagenin: Serotonin, norepinephrine and dopamine reuptake inhibitor. Pharmacol. Biochem. Behav.100, 431–439. 10.1016/j.pbb.2011.10.001

  • CrossRef
  • Google Scholar

• 139

  Joshi P. Bisht A. Joshi S. Semwal D. Nema N. K. Dwivedi J. et al (2022). Ameliorating potential of curcumin and its analogue in central nervous system disorders and related conditions: A review of molecular pathways. Phytother. Res.36, 3143–3180. 10.1002/ptr.7522

  • CrossRef
  • Google Scholar

• 140

  Josiah S. S. Famusiwa C. D. Crown O. O. Lawal A. O. Olaleye M. T. Akindahunsi A. A. et al (2022). Neuroprotective effects of catechin and quercetin in experimental Parkinsonism through modulation of dopamine metabolism and expression of IL-1β, TNF-α, NF-κB, IκKB, and p53 genes in male Wistar rats. Neurotoxicology90, 158–171. 10.1016/j.neuro.2022.03.004

  • CrossRef
  • Google Scholar

• 141

  Jung J. W. Cho J. H. Ahn N. Y. Oh H. R. Kim S. Y. Jang C. G. et al (2005). Effect of chronic Albizzia julibrissin treatment on 5-hydroxytryptamine1A receptors in rat brain. Pharmacol. Biochem. Behav.81, 205–210. 10.1016/j.pbb.2005.03.014

  • CrossRef
  • Google Scholar

• 142

  Jyotirmayee B. Mahalik G. (2022). A review on selected pharmacological activities of Curcuma longa L. Int. J. Food Prop.25, 1377–1398. https://doi.org/10.1080/10942912.2022.2082464.

  • Google Scholar

• 143

  Kalinderi K. Bostantjopoulou S. Fidani L. (2016). The genetic background of Parkinson's disease: Current progress and future prospects. Acta Neurol. Scand.134, 314–326. 10.1111/ane.12563

  • CrossRef
  • Google Scholar

• 144

  Karim N. Khan I. Abdelhalim A. Halim S. A. Khan A. Al-Harrasi A. (2021). Stigmasterol can be new steroidal drug for neurological disorders: Evidence of the GABAergic mechanism via receptor modulation. Phytomedicine.90, 153646. 10.1016/j.phymed.2021.153646

  • CrossRef
  • Google Scholar

• 145

  Karkada G. Shenoy K. B. Halahalli H. Karanth K. (2012). Nardostachys jatamansi extract prevents chronic restraint stress-induced learning and memory deficits in a radial arm maze task. J. Nat. Sci. Biol. Med.3, 125–132. 10.4103/0976-9668.101879

  • CrossRef
  • Google Scholar

• 146

  Kaswan K. S. Gaur L. Dhatterwal J. S. Kumar R. (2021). Advanced AI techniques and applications in bioinformatics. Boca Raton, FL: CRC Press, 41–86. 10.1201/9781003126164AI-based natural language processing for the generation of meaningful information electronic health record (EHR) data

  • CrossRef
  • Google Scholar

• 147

  Katila N. Duwa R. Bhurtel S. Khanal S. Maharjan S. Jeong J. H. et al (2022). Enhancement of blood–brain barrier penetration and the neuroprotective effect of resveratrol. J. Control. Release346, 1–19. 10.1016/j.jconrel.2022.04.003

  • CrossRef
  • Google Scholar

• 148

  Katsumoto A. Takeuchi H. Tanaka F. (2019). Tau pathology in chronic traumatic encephalopathy and alzheimer's disease: Similarities and differences. Front. Neurol.10, 980. 10.3389/fneur.2019.00980

  • CrossRef
  • Google Scholar

• 149

  Kaur J. Famta P. Famta M. Mehta M. Satija S. Sharma N. et al (2021). Potential anti-epileptic phytoconstituents: An updated review. J. Ethnopharmacol.268, 113565. 10.1016/j.jep.2020.113565

  • CrossRef
  • Google Scholar

• 150

  Kay C. Collins J. A. Skotte N. H. Southwell A. L. Warby S. C. Caron N. S. et al (2015). Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. Mol. Ther.23, 1759–1771. 10.1038/mt.2015.128

  • CrossRef
  • Google Scholar

• 151

  Kennedy D. O. Pace S. Haskell C. Okello E. J. Milne A. Scholey A. B. (2006). Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stress or battery. Neuropsychopharmacology31, 845–852. 10.1038/sj.npp.1300907

  • CrossRef
  • Google Scholar

• 152

  Kent S. A.-O. Spires-Jones T. A.-O. Durrant C. A.-O. (2020). The physiological roles of tau and Aβ: Implications for alzheimer's disease pathology and therapeutics. Acta Neuropathol.417, 417–447. 10.1007/s00401-020-02196-w

  • CrossRef
  • Google Scholar

• 153

  Khan H. Perviz S. Sureda A. Nabavi S. M. Tejada S. (2018). Current standing of plant derived flavonoids as an antidepressant. Food Chem. Toxicol.119, 176–188. 10.1016/j.fct.2018.04.052

  • CrossRef
  • Google Scholar

• 154

  Khyati, Malik I. Agrawal N. Kumar V. (2021). Melatonin and curcumin reestablish disturbed circadian gene expressions and restore locomotion ability and eclosion behavior in Drosophila model of Huntington’s disease. Chronobiol. Int.38, 61–78. 10.1080/07420528.2020.1842752

  • CrossRef
  • Google Scholar

• 155

  Kim H. J. Taylor J. P. (2017). Lost in transportation: Nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron96, 285–297. 10.1016/j.neuron.2017.07.029

  • CrossRef
  • Google Scholar

• 156

  Kim S. Yang M. Ku B. Cha E. Seo W. Son I. et al (2022). Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial, KCT0001984. 10.2139/ssrn.4086326

  • CrossRef
  • Google Scholar

• 157

  Kim W. K. Jung J. W. Ahn N. Y. Oh H. R. Lee B. K. Oh J. K. et al (2004). Anxiolytic-like effects of extracts from Albizzia julibrissin bark in the elevated plus-maze in rats. Life Sci.75, 2787–2795. 10.1016/j.lfs.2004.05.024

  • CrossRef
  • Google Scholar

• 158

  Kimura Y. Sumiyoshi M. (2011). Effects of various flavonoids isolated from Scutellaria baicalensis roots on skin damage in acute UVB-irradiated hairless mice. J. Pharm. Pharmacol.63, 1613–1623. 10.1111/j.2042-7158.2011.01365.x

  • CrossRef
  • Google Scholar

• 159

  Klvana M. Chen J. Lépine F. Legros R. Jolicoeur M. (2006). Analysis of secondary metabolites from Eschscholtzia californica by high-performance liquid chromatography. Phytochem. Anal.17, 236–242. 10.1002/pca.913

  • CrossRef
  • Google Scholar

• 160

  Kodimule P. S. (2021). “Method of using a chlorogenic acid composition for supporting cognitive function,”. US20210330627.

  • Google Scholar

• 161

  Kruse N. Schulz-Schaeffer W. J. Schlossmacher M. G. Mollenhauer B. (2012). Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Methods56, 514–518. 10.1016/j.ymeth.2012.03.016

  • CrossRef
  • Google Scholar

• 162

  Kumar G. P. Anilakumar K. R. Naveen S. (2015). Phytochemicals having neuroprotective properties from dietary sources and medicinal herbs. Phcog. J.7, 1–17. 10.5530/pj.2015.7.1

  • CrossRef
  • Google Scholar

• 163

  Kumar M. P. Nagnath K. R. (2021). “Isolation and identification of suitable anticonvulsant drug from Cucurbita maxima,”. IN202121057739.

  • Google Scholar

• 164

  Kumar S. Madaan R. Sharma A. (2008). Estimation of apigenin, an anxiolytic constituent, in Turnera aphrodisiaca. Indian J. Pharm. Sci.70, 847–851. 10.4103/0250-474X.49143

  • CrossRef
  • Google Scholar

• 165

  Kumar S. Sharma A. (2005). Anti-anxiety activity studies of various extracts of Turnera aphrodisiaca Ward. J. Herb. Pharmacother.5, 13–21. 10.1080/J157v05n04_02

  • CrossRef
  • Google Scholar

• 166

  Kundap U. P. Bhuvanendran S. Kumari Y. Othman I. Shaikh M. F. (2017). Plant derived phytocompound, embelin in CNS disorders: A systematic review. Front. Pharmacol.8, 76. 10.3389/fphar.2017.00076

  • CrossRef
  • Google Scholar

• 167

  Kuribara H. Weintraub S. T. Yoshihama T. Maruyama Y. (2003). An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice. J. Nat. Prod.66, 1333–1337. 10.1021/np030122f

  • CrossRef
  • Google Scholar

• 168

  Labban S. Alghamdi B. S. Alshehri F. S. Kurdi M. (2021). Effects of melatonin and resveratrol on recognition memory and passive avoidance performance in a mouse model of Alzheimer’s disease. Behav. Brain Res.402, 113100. 10.1016/j.bbr.2020.113100

  • CrossRef
  • Google Scholar

• 169

  Lanhers M. C. Fleurentin J. Cabalion P. Rolland A. Dorfman P. Misslin R. et al (1990). Behavioral effects of Euphorbia hirta L.: Sedative and anxiolytic properties. J. Ethnopharmacol.29, 189–198. 10.1016/0378-8741(90)90055-X

  • CrossRef
  • Google Scholar

• 170

  Lee S. A. Hong S. S. Han X. H. Hwang J. S. Oh G. J. Lee K. S. et al (2005). Piperine from the fruits of Piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem. Pharm. Bull.53, 832–835. 10.1248/cpb.53.832

  • CrossRef
  • Google Scholar

• 171

  Lee S. A. Hwang J. S. Han X. H. Lee C. Lee M. H. Choe S. G. et al (2008). Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidase. Arch. Pharm. Res.31, 679–683. 10.1007/s12272-001-1212-7

  • CrossRef
  • Google Scholar

• 172

  Li R. Wang Z. M. Wang Y. Dong X. Zhang L. H. Wang T. et al (2021). Antidepressant activities and regulative effects on serotonin transporter of Nardostachys jatamansi DC. J. Ethnopharmacol.268, 113601. 10.1016/j.jep.2020.113601

  • CrossRef
  • Google Scholar

• 173

  Li W. Zhao J. Shen C. Zhang J. Hu J. Xiao M. et al (2022). Regional brain fusion: Graph convolutional network for alzheimer's disease prediction and analysis. Front. Neuroinform.16, 886365. 10.3389/fninf.2022.886365

  • CrossRef
  • Google Scholar

• 174

  Li X. X. He G. R. Mu X. Xu B. Tian S. Yu X. et al (2012). Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria. Eur. J. Pharmacol.674, 227–233. 10.1016/j.ejphar.2011.09.181

  • CrossRef
  • Google Scholar

• 175

  Liang Y. Ye C. Chen Y. Chen Y. Diao S. Huang M. (2021). Berberine improves behavioral and cognitive deficits in a mouse model of Alzheimer’s disease via regulation of β-amyloid production and endoplasmic reticulum stress. ACS Chem. Neurosci.12, 1894–1904. 10.1021/acschemneuro.0c00808

  • CrossRef
  • Google Scholar

• 176

  Lill C. M. (2016). Genetics of Parkinson's disease. Mol. Cell. Probes30, 386–396. 10.1016/j.mcp.2016.11.001

  • CrossRef
  • Google Scholar

• 177

  Lill C. M. Klein C. (2017). Epidemiology and causes of Parkinson’s disease. Nervenarzt88, 345–355. 10.1007/s00115-017-0288-0

  • CrossRef
  • Google Scholar

• 178

  Lima Z. P. dos Santos R. D. Torres T. U. Sannomiya M. Rodrigues C. M. dos Santos L. C. et al (2008). Byrsonima fagifolia: An integrative study to validate the gastroprotective, healing, antidiarrheal, antimicrobial and mutagenic action. J. Ethnopharmacol.120, 149–160. 10.1016/j.jep.2008.07.047

  • CrossRef
  • Google Scholar

• 179

  Lindberg I. Shorter J. Wiseman R. L. Chiti F. Dickey C. A. McLean P. J. (2015). Chaperones in neurodegeneration. J. Neurosci.35, 13853–13859. 10.1523/jneurosci.2600-15.2015

  • CrossRef
  • Google Scholar

• 180

  Liu W. Wu L. Liu W. Tian L. Chen H. Wu Z. et al (2022). Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer's disease. Eur. J. Med. Chem.242, 114689. 10.1016/j.ejmech.2022.114689

  • CrossRef
  • Google Scholar

• 181

  Lopes I. S. Oliveira I. C. Capibaribe V. C. Valentim J. T. da Silva D. M. de Souza A. G. et al (2018). Riparin II ameliorates corticosterone-induced depressive-like behavior in mice: Role of antioxidant and neurotrophic mechanisms. Neurochem. Int.120, 33–42. 10.1016/j.neuint.2018.07.007

  • CrossRef
  • Google Scholar

• 182

  López-Cruz L. Salamone J. D. Correa M. (2018). Caffeine and selective adenosine receptor antagonists as new therapeutic tools for the motivational symptoms of depression. Front. Pharmacol.9, 526. 10.3389/fphar.2018.00526

  • CrossRef
  • Google Scholar

• 183

  Lopresti A. L. (2018). The problem of curcumin and its bioavailability: Could its gastrointestinal influence contribute to its overall health-enhancing effects?Adv. Nutr.9, 41–50. 10.1093/advances/nmx011

  • CrossRef
  • Google Scholar

• 184

  Lu J. Wang X. Wu A. Cao Y. Dai X. Liang Y. et al (2022). Ginsenosides in central nervous system diseases: Pharmacological actions, mechanisms, and therapeutics. Phytother. Res.36, 1523–1544. 10.1002/ptr.7395

  • CrossRef
  • Google Scholar

• 185

  Lum P. T. Sekar M. Gan S. H. Bonam S. R. Shaikh M. F. (2021). Protective effect of natural products against Huntington’s disease: An overview of scientific evidence and understanding their mechanism of action. ACS Chem. Neurosci.12, 391–418. 10.1021/acschemneuro.0c00824

  • CrossRef
  • Google Scholar

• 186

  Ma W. Kuang H. Wang L. Xu L. Chang W. S. Zhang H. et al (2013). Chiral plasmonics of self-assembled nanorod dimers. Sci. Rep.3, 1934–1936. 10.1038/srep01934

  • CrossRef
  • Google Scholar

• 187

  Machado D. G. Cunha M. P. Neis V. B. Balen G. O. Colla A. Bettio L. E. et al (2013). Antidepressant-like effects of fractions, essential oil, carnosol and betulinic acid isolated from Rosmarinus officinalis L. Food Chem.136, 999–1005. 10.1016/j.foodchem.2012.09.028

  • CrossRef
  • Google Scholar

• 188

  Machado D. G. Neis V. B. Balen G. O. Colla A. Cunha M. P. Dalmarco J. B. et al (2012). Antidepressant-like effect of ursolic acid isolated from Rosmarinus officinalis L. In mice: Evidence for the involvement of the dopaminergic system. Pharmacol. Biochem. Behav.103, 204–211. 10.1016/j.pbb.2012.08.016

  • CrossRef
  • Google Scholar

• 189

  Mahanti N. K. Upendar K. Chakraborty S. K. (2022). Comparison of artificial neural network and linear regression model for the leaf morphology of fenugreek (Trigonella foenum graecum) grown under different nitrogen fertilizer doses. Smart Agric. Technol.2, 100058. 10.1016/j.atech.2022.100058

  • CrossRef
  • Google Scholar

• 190

  Malik J. Kaur S. Karan M. Choudhary S. (2022). Neuroprotective effect of standardized extracts of three Lactuca sativa Linn. varieties against 3-NP induced Huntington’s disease like symptoms in rats. Nutr. Neurosci.25, 1173–1187. 10.1080/1028415X.2020.1841500

  • CrossRef
  • Google Scholar

• 191

  Manasa K. Vellapandian C. Vasanthan M. M. Jaisankar N. (2022). Phytochemical extract containing indole alkaloid camalexin for management of benomyl induced Parkinson’s disease. 21. IN202141020016.

  • Google Scholar

• 192

  Mannan A. Singh T. G. Singh V. Garg N. Kaur A. Singh M. (2022). Insights into the mechanism of the therapeutic potential of herbal monoamine oxidase inhibitors in neurological diseases. Curr. Drug Targets23, 286–310. 10.2174/1389450122666210707120256

  • CrossRef
  • Google Scholar

• 193

  Mannucci C. Navarra M. Calzavara E. Caputi A. P. Calapai G. (2012). Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats. Phytomedicine19, 1117–1124. 10.1016/j.phymed.2012.07.001

  • CrossRef
  • Google Scholar

• 194

  Mantovani A. Allavena P. Sica A. Balkwill F. (2008). Cancer-related inflammation. Nature454, 436–444. 10.1038/nature07205

  • CrossRef
  • Google Scholar

• 195

  Mao Q. Huang Z. Ip S. Che C. (2008). Antidepressant-like effect of ethanol extract from Paeonia lactiflora in mice. Phytother. Res.22, 1496–1499. 10.1002/ptr.2519

  • CrossRef
  • Google Scholar

• 196

  Mao Q. Q. Ip S. P. Tsai S. H. Che C. T. (2008). Antidepressant-like effect of peony glycosides in mice. J. Ethnopharmacol.119, 272–275. 10.1016/j.jep.2008.07.008

  • CrossRef
  • Google Scholar

• 197

  Mao X.-Y. Zhou H.-H. Jin W.-L. (2019). Redox-related neuronal death and crosstalk as drug targets: Focus on epilepsy. Front. Neurosci.13, 512. 10.3389/fnins.2019.00512

  • CrossRef
  • Google Scholar

• 198

  Marí M. Colell A. (2021). Mitochondrial oxidative and nitrosative stress as a therapeutic target in diseases. Antioxidants10, 314. 10.3390/antiox10020314

  • CrossRef
  • Google Scholar

• 199

  Martins J. Brijesh S. (2018). Phytochemistry and pharmacology of anti-depressant medicinal plants: A review. Biomed. Pharmacother.104, 343–365. 10.1016/j.biopha.2018.05.044

  • CrossRef
  • Google Scholar

• 200

  Martins M. Silva R. Pinto M. M. M. Sousa E. (2020). Marine natural products, multitarget therapy and repurposed agents in Alzheimer's disease. Pharm. (Basel)13, 242. 10.3390/ph13090242

  • CrossRef
  • Google Scholar

• 201

  Mashayekh A. Pham D. L. Yousem D. M. Dizon M. Barker P. B. Lin D. D. (2021). Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: A pilot study. Neuroradiology53, 185–191. 10.1007/s00234-010-0790-6

  • CrossRef
  • Google Scholar

• 202

  Mathew J. Balakrishnan S. Antony S. Abraham P. M. Paulose C. S. (2012). Decreased GABA receptor in the cerebral cortex of epileptic rats: Effect of Bacopa monnieri and bacoside-A. J. Biomed. Sci.19, 25. 10.1186/1423-0127-19-25

  • CrossRef
  • Google Scholar

• 203

  Mathur D. Goyal K. Koul V. Anand A. (2016). The molecular links of re-emerging therapy: A review of evidence of brahmi (Bacopa monniera). Front. Pharmacol.7, 44. 10.3389/fphar.2016.00044

  • CrossRef
  • Google Scholar

• 204

  McCarthy B. O’Neill G. Abu-Ghannam N. (2022). Potential psychoactive effects of microalgal bioactive compounds for the case of sleep and mood regulation: Opportunities and challenges. Mar. Drugs20, 493. 10.3390/md20080493

  • CrossRef
  • Google Scholar

• 205

  Mehringer J. Navarro J. A. Touraud D. Schneuwly S. Kunz W. (2022). Phosphorylated resveratrol as a protein aggregation suppressor in vitro and in vivo. RSC Chem. Biol.3, 2250–2260. https://doi.org/10.1039/D1CB00220A.

  • Google Scholar

• 206

  Mendonça-Junior F. J. Scotti M. T. Muratov E. N. Scotti L. Nayarisseri A. (2021). Natural bioactive products with antioxidant properties useful in neurodegenerative diseases 2020. Oxid. Med. Cell. Longev.2021, 6262316. 10.1155/2021/6262316

  • CrossRef
  • Google Scholar

• 207

  Merzougui W. H. Myers M. A. Hall S. Elmansouri A. Parker R. Robson A. D. et al (2021). Multiple-choice versus open-ended questions in advanced clinical neuroanatomy: Using a national neuroanatomy assessment to investigate variability in performance using different question types. Anat. Sci. Educ.14, 296–305. 10.1002/ase.2053

  • CrossRef
  • Google Scholar

• 208

  Miranda M. Morici J. F. Zanoni M. B. Bekinschtein P. (2019). Brain-derived neurotrophic factor: A key molecule for memory in the healthy and the pathological brain. Front. Cell. Neurosci.13, 363. 10.3389/fncel.2019.00363

  • CrossRef
  • Google Scholar

• 209

  Mitra S. Muni M. Shawon N. J. Das R. Emran T. B. Sharma R. et al (2022). Tacrine derivatives in neurological disorders: Focus on molecular mechanisms and neurotherapeutic potential. Oxid. Med. Cell. Longev.2022, 7252882. 10.1155/2022/7252882

  • CrossRef
  • Google Scholar

• 210

  Mo Y. Xu E. Wei R. Le B. Song L. Li D. et al (2018). Bushen-yizhi formula alleviates neuroinflammation via inhibiting NLRP3 inflammasome activation in a mouse model of Parkinson’s disease. Evid. Based. Complement. Altern. Med.2018. 10.1155/2018/35716043571604

  • CrossRef
  • Google Scholar

• 211

  Mohammadi A. Colagar A. H. Khorshidian A. Amini S. M. (2022). The functional roles of curcumin on astrocytes in neurodegenerative diseases. Neuroimmunomodulation29, 4–14. 10.1159/000517901

  • CrossRef
  • Google Scholar

• 212

  Mohebali N. ShahzadehFazeli S. A. Ghafoori H. Farahmand Z. MohammadKhani E. Vakhshiteh F. et al (2018). Effect of flavonoids rich extract of Capparis spinosa on inflammatory involved genes in amyloid-beta peptide injected rat model of Alzheimer's disease. Nutr. Neurosci.21, 143–150. 10.1080/1028415X.2016.1238026

  • CrossRef
  • Google Scholar

• 213

  Mora S. Díaz-Véliz G. Millán R. Lungenstrass H. Quirós S. Coto-Morales T. et al (2005). Anxiolytic and antidepressant-like effects of the hydroalcoholic extract from Aloysia polystachya in rats. Pharmacol. Biochem. Behav.82, 373–378. 10.1016/j.pbb.2005.09.007

  • CrossRef
  • Google Scholar

• 214

  Morales P. Reggio P. H. Jagerovic N. (2017). An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front. Pharmacol.8, 422. 10.3389/fphar.2017.00422

  • CrossRef
  • Google Scholar

• 215

  Movafegh A. Alizadeh R. Hajimohamadi F. Esfehani F. Nejatfar M. (2008). Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: A double-blind, placebo-controlled study. Anesth. Analg.106, 1728–1732. 10.1213/ane.0b013e318172c3f9

  • CrossRef
  • Google Scholar

• 216

  Murphy M. P. Hartley R. C. (2018). Mitochondria as a therapeutic target for common pathologies. Nat. Rev. Drug Discov.17, 865–886. 10.1038/nrd.2018.174

  • CrossRef
  • Google Scholar

• 217

  Mursaleen L. R. Stamford J. A. Jones D. A. Windle R. Isaacs T. (2017). Attitudes towards data collection, ownership and sharing among patients with Parkinson's disease. J. Park. Dis.7, 523–531. 10.3233/JPD-161045

  • CrossRef
  • Google Scholar

• 218

  Muzaffar K. Sofi S. A. Makroo H. A. Majid D. Dar B. N. (2022). Insight about the biochemical composition, postharvest processing, therapeutic potential of Indian gooseberry (amla), and its utilization in development of functional foods—A comprehensive review. J. Food Biochem.1. e14132. 10.1111/jfbc.14132

  • CrossRef
  • Google Scholar

• 219

  Nakazawa T. Yasuda T. Ueda J. Ohsawa K. (2003). Antidepressant-like effects of apigenin and 2, 4, 5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. Biol. Pharm. Bull.26, 474–480. 10.1248/bpb.26.474

  • CrossRef
  • Google Scholar

• 220

  Naoi M. Maruyama W. (2010). Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des.16, 2799–2817. 10.2174/138161210793176527

  • CrossRef
  • Google Scholar

• 221

  Navarro E. Alonso S. J. Trujillo J. Jorge E. Pérez C. (2004). Central nervous activity of elenoside. Phytomedicine11, 498–503. 10.1016/j.phymed.2003.06.003

  • CrossRef
  • Google Scholar

• 222

  Neag M. A. Mocan A. Echeverría J. Pop R. M. Bocsan C. I. Crişan G. et al (2018). Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front. Pharmacol.9, 557. 10.3389/fphar.2018.00557

  • CrossRef
  • Google Scholar

• 223

  Nebrisi E. E. (2021). Neuroprotective activities of curcumin in Parkinson’s disease: A review of the literature. Int. J. Mol. Sci.22, 11248. https://doi.org/10.3390/ijms222011248.

  • Google Scholar

• 224

  Nemeth E. Bernath J. (2008). Biological activities of yarrow species (Achillea spp.)Curr. Pharm. Des.14, 3151–3167. 10.2174/138161208786404281

  • CrossRef
  • Google Scholar

• 225

  Noor N. A. Hosny E. N. Khadrawy Y. A. Mourad I. M. Othman A. I. Aboul Ezz H. S. et al (2022). Effect of curcumin nanoparticles on streptozotocin-induced male wistar rat model of Alzheimer’s disease. Metab. Brain Dis.37, 343–357. 10.1007/s11011-021-00897-z

  • CrossRef
  • Google Scholar

• 226

  Nunes A. Sousa M. (2011). Use of valerian in anxiety and sleep disorders: What is the best evidence?Acta Med. Port.24, 961–966.

  • Google Scholar

• 227

  Palkar J. Prasad R. (2021). “Synergistic nutritional compositions for treating cerebrovascular diseases,”. WO/2021/084559.

  • Google Scholar

• 228

  Pan G. King A. Wu F. Simpson-Yap S. Woodhouse A. Phipps A. et al (2021). The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer’s disease. Ageing Res. Rev.70, 101402. 10.1016/j.arr.2021.101402

  • CrossRef
  • Google Scholar

• 229

  Pan Y. Zhao X. Wang Y. Tan J. Chen D. X. (2021). Metabolomics integrated with transcriptomics reveals the distribution of iridoid and crocin metabolic flux in Gardenia jasminoides Ellis. Plos One16, e0256802. 10.1371/journal.pone.0256802

  • CrossRef
  • Google Scholar

• 230

  Pandey M. M. Rastogi S. Rawat A. K. (2013). Indian traditional ayurvedic system of medicine and nutritional supplementation. Evid. Based. Complement. Altern. Med.2013. 10.1155/2013/376327376327

  • CrossRef
  • Google Scholar

• 231

  Pase M. P. Kean J. Sarris J. Neale C. Scholey A. B. Stough C. (2012). The cognitive-enhancing effects of Bacopa monnieri: A systematic review of randomized, controlled human clinical trials. J. Altern. Complement. Med.18, 647–652. 10.1089/acm.2011.0367

  • CrossRef
  • Google Scholar

• 232

  Patil P. Thakur A. Sharma A. Flora S. J. S. (2020). Natural products and their derivatives as multifunctional ligands against alzheimer's disease. Drug Dev. Res.81, 165–183. 10.1002/ddr.21587

  • CrossRef
  • Google Scholar

• 233

  Patil R. A. Hiray Y. A. Kasture S. B. (2012). Reversal of reserpine-induced orofacial dyskinesia and catalepsy by Nardostachys jatamansi. Indian J. Pharmacol.44, 340–344. 10.4103/0253-7613.96307

  • CrossRef
  • Google Scholar

• 234

  Pearson-Smith J. N. Liang L. P. Rowley S. D. Day B. J. Patel M. (2017). Oxidative stress contributes to status epilepticus associated mortality. Neurochem. Res.42, 2024–2032. 10.1007/s11064-017-2273-1

  • CrossRef
  • Google Scholar

• 235

  Pérez-Arancibia R. Ordoñez J. L. Rivas A. Pihán P. Sagredo A. Ahumada U. et al (2021). A phenolic-rich extract from Ugnimolinae berries reduces abnormal protein aggregation in a cellular model of Huntington’s disease. PloS One16, 0254834. 10.1371/journal.pone.0254834

  • CrossRef
  • Google Scholar

• 236

  Perrone D. Fuggetta M. P. Ardito F. Cottarelli A. De Filippis A. Ravagnan G. et al (2017). Resveratrol (3, 5, 4’-trihydroxystilbene) and its properties in oral diseases. Exp. Ther. Med.14, 3–9. 10.3892/etm.2017.4472

  • CrossRef
  • Google Scholar

• 237

  Piato Â. L. Rizon L. P. Martins B. S. Nunes D. S. Elisabetsky E. (2009). Antidepressant profile of Ptychopetalum olacoides bentham (marapuama) in mice. Phytother. Res.23, 519–524. 10.1002/ptr.2664

  • CrossRef
  • Google Scholar

• 238

  Pitsikas N. Boultadakis A. Georgiadou G. Tarantilis P. A. Sakellaridis N. (2008). Effects of the active constituents of Crocus sativus L., crocins, in an animal model of anxiety. Phytomedicine15, 1135–1139. 10.1016/j.phymed.2008.06.005

  • CrossRef
  • Google Scholar

• 239

  Pohl F. Kong Thoo Lin P. (2018). The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: In vitro, in vivo and clinical trials. Molecules23, 3283. 10.3390/molecules23123283

  • CrossRef
  • Google Scholar

• 240

  Porcari G. S. Fu C. Doll E. D. Carter E. G. Carson R. P. (2018). Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav.80, 240–246. 10.1016/j.yebeh.2018.01.026

  • CrossRef
  • Google Scholar

• 241

  Prandi C. Blangetti M. Namdar D. Koltai H. (2018). Structure-activity relationship of cannabis derived compounds for the treatment of neuronal activity-related diseases. Molecules23, 1526. 10.3390/molecules23071526

  • CrossRef
  • Google Scholar

• 242

  Pu J. Li X. N. D. D. N. (2018). Nddn: A cloud-based neuroinformation database for developing neuronal networks. J. Healthc. Eng.2018. 3839094. 10.1155/2018/3839094

  • CrossRef
  • Google Scholar

• 243

  Purushothaman B. Sumathi T. (2022). 5, 6, 7-Trihydroxy flavone armoured neurodegeneration caused by quinolinic acid induced Huntington’s like disease in rat striatum-reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathological aspects. Neurosci. Res.174, 25–35. 10.1016/j.neures.2021.08.003

  • CrossRef
  • Google Scholar

• 244

  Qiu F. Zhong X. Mao Q. Huang Z. (2013). The antidepressant-like effects of paeoniflorin in mouse models. Exp. Ther. Med.5, 1113–1116. 10.3892/etm.2013.925

  • CrossRef
  • Google Scholar

• 245

  Qiu T. Wu D. Yang L. Ye H. Wang Q. Cao Z. et al (2018). Exploring the mechanism of flavonoids through systematic bioinformatics analysis. Front. Pharmacol.9, 918. 10.3389/fphar.2018.00918

  • CrossRef
  • Google Scholar

• 246

  Rahman M. Islam M. R. Mim M. Akash S. Noor Alam M. Nepovimova E. et al (2022). Exploring the role of nano-medicines for the therapeutic approach of central nervous system dysfunction: At a glance. Front. Cell Dev. Biol.1780, 989471. 10.3389/fcell.2022.989471

  • CrossRef
  • Google Scholar

• 247

  Raihan M. O. Habib M. R. Brishti A. Rahman M. M. Saleheen M. M. Manna M. (2011). Sedative and anxiolytic effects of the methanolic extract of Leea indica (Burm. f.) Merr. leaf. Drug Discov. Ther.5, 185–189. 10.5582/ddt.2011.v5.4.185

  • CrossRef
  • Google Scholar

• 248

  Ramachandra V. H. Sivanesan S. Koppal A. Anandakumar S. Howell M. D. Sukumar E. et al (2022). Embelin and levodopa combination therapy for improved Parkinson’s disease treatment. Transl. Neurosci.13, 145–162. 10.1515/tnsci-2022-0224

  • CrossRef
  • Google Scholar

• 249

  Ramires Júnior O. V. Alves B. D. Barros P. A. Rodrigues J. L. Ferreira S. P. Monteiro L. K. et al (2021). Nanoemulsion improves the neuroprotective effects of curcumin in an experimental model of Parkinson’s disease. Neurotox. Res.39, 787–799. 10.1007/s12640-021-00362-w

  • CrossRef
  • Google Scholar

• 250

  Ranjbar M. Mazaheri M. Ansaripour M. Babaeian M. Jalali A. Zarshenas M. M. (2022). Herbal medications to manage insomnia: An overview of clinical trials using herbal treatment for insomnia. Trad. Integr. Med.1. 254–265. 10.18502/tim.v7i2.9928

  • CrossRef
  • Google Scholar

• 251

  Rapaka D. Bitra V. R. Ummidi R. Akula A. (2021). Benincasa hispida alleviates amyloid pathology by inhibition of keap1/nrf2-axis: Emphasis on oxidative and inflammatory stress involved in alzheimer's disease model. Neuropeptides88, 102151. 10.1016/j.npep.2021.102151

  • CrossRef
  • Google Scholar

• 252

  Rastogi S. Baiswar A. Nischal A. Srivastava P. S. Nischal A. (2016). Effects of shirodhara in generalized anxiety disorder. Cell Med.6, 27. 10.5667/tang.2016.0016

  • CrossRef
  • Google Scholar

• 253

  Rastogi S. (2010). Building bridges between ayurveda and modern science. Int. J. Ayurveda Res.1, 41–46. 10.4103/0974-7788.59943

  • CrossRef
  • Google Scholar

• 254

  Rastogi S. (2019). Coma with glasgow coma scale score 3 at admission following acute head injury: Experiencing the complete recovery supported through ayurveda–a case report. Complement. Med. Res.26, 353–360. 10.1159/000498912

  • CrossRef
  • Google Scholar

• 255

  Rastogi S. (2014). Rehabilitative potential of ayurveda for neurological deficits caused by traumatic spinal cord injury. J. Ayurveda Integr. Med.5, 56–59. 10.4103/0975-9476.128868

  • CrossRef
  • Google Scholar

• 256

  Ratcliffe C. Wandschneider B. Baxendale S. Thompson P. Koepp M. J. Caciagli L. (2020). Cognitive function in genetic generalized epilepsies: Insights from neuropsychology and neuroimaging. Front. Neurol.11, 144. 10.3389/fneur.2020.00144

  • CrossRef
  • Google Scholar

• 257

  Raucci U. Pietrafusa N. Paolino M. C. Di Nardo G. Villa M. P. Pavone P. et al (2020). Cannabidiol treatment for refractory epilepsies in pediatrics. Front. Pharmacol.11, 586110. 10.3389/fphar.2020.586110

  • CrossRef
  • Google Scholar

• 258

  Ravid D. (2022). A combination therapy comprising uncaria for treating anxiety and depression. WO/2022/123572.

  • Google Scholar

• 259

  Ravikumar B. Aittokallio T. (2018). Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert Opin. Drug Discov.13, 179–192. 10.1080/17460441.2018.1413089

  • CrossRef
  • Google Scholar

• 260

  Rehman M. U. Wali A. F. Ahmad A. Shakeel S. Rasool S. Ali R. et al (2019). Neuroprotective strategies for neurological disorders by natural products: An update. Curr. Neuropharmacol.17, 247–267. 10.2174/1570159X16666180911124605

  • CrossRef
  • Google Scholar

• 261

  Ren L. X. Luo Y. F. Li X. Zuo D. Y. Wu Y. L. (2006). Antidepressant-like effects of sarsasapogenin from Anemarrhena asphodeloides B UNGE (liliaceae). Biol. Pharm. Bull.29, 2304–2306. 10.1248/bpb.29.2304

  • CrossRef
  • Google Scholar

• 262

  Ren Q. Jiang X. Paudel Y. N. Gao X. Gao D. Zhang P. et al (2022). Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson’s disease like pathology in zebrafish. J. Ethnopharmacol.292, 115234. 10.1016/j.jep.2022.115234

  • CrossRef
  • Google Scholar

• 263

  Resstel L. B. Tavares R. F. Lisboa S. F. Joca S. R. Corrêa F. M. Guimarães F. S. (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol.156, 181–188. 10.1111/j.1476-5381.2008.00046.x

  • CrossRef
  • Google Scholar

• 264

  Rho J. M. Boison D. (2022). The metabolic basis of epilepsy. Nat. Rev. Neurol.18, 333–347. 10.1038/s41582-022-00651-8

  • CrossRef
  • Google Scholar

• 265

  Roda A. R. Serra-Mir G. Montoliu-Gaya L. Tiessler L. Villegas S. (2022). Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural Regen. Res.17, 1666–1674. 10.4103/1673-5374.332127

  • CrossRef
  • Google Scholar

• 266

  Rodrigues A. L. da Silva G. L. Mateussi A. S. Fernandes E. S. Miguel O. G. Yunes R. A. et al (2002). Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci.70, 1347–1358. 10.1016/S0024-3205(01)01498-9

  • CrossRef
  • Google Scholar

• 267

  Rolland A. Fleurentin J. Lanhers M. C. Misslin R. Mortier F. (2001). Neurophysiological effects of an extract of Eschscholzia californica cham.(papaveraceae). Phytother. Res.15, 377–381. 10.1002/ptr.884

  • CrossRef
  • Google Scholar

• 268

  Rolland A. Fleurentin J. Lanhers M. C. Younos C. Misslin R. Mortier F. et al (1991). Behavioural effects of the American traditional plant Eschscholzia californica: Sedative and anxiolytic properties. Planta Med.57, 212–216. 10.1055/s-2006-960076

  • CrossRef
  • Google Scholar

• 269

  Ruiz-Olazar M. Rocha E. S. Vargas C. D. Braghetto K. R. (2021). The neuroscience experiments system (nes)-a software tool to manage experimental data and its provenance. Front. Neuroinform.77, 768615. 10.3389/fninf.2021.768615

  • CrossRef
  • Google Scholar

• 270

  Ryan M. (2020). Cannabidiol in epilepsy: The indications and beyond. Ment. Health Clin.10, 317–325. 10.9740/mhc.2020.11.317

  • CrossRef
  • Google Scholar

• 271

  Sah S. P. Mathela C. S. Chopra K. (2011). Antidepressant effect of Valerianawallichii patchouli alcohol chemotype in mice: Behavioural and biochemical evidence. J. Ethnopharmacol.135, 197–200. 10.1016/j.jep.2011.02.018

  • CrossRef
  • Google Scholar

• 272

  Sah S. P. Mathela C. S. Chopra K. (2011). Involvement of nitric oxide (NO) signalling pathway in the antidepressant activity of essential oil of Valerianawallichii Patchouli alcohol chemotype. Phytomedicine18, 1269–1275. 10.1016/j.phymed.2011.06.009

  • CrossRef
  • Google Scholar

• 273

  Saha T. Saha S. Karmakar A. Chatterjee M. Maitra S. Sinha S. et al (2022). Differential effect of folate metabolic system genetic variants on attention deficit hyperactivity disorder severity. Hum. Gene34, 201096. 10.1016/j.humgen.2022.201096

  • CrossRef
  • Google Scholar

• 274

  Sairam K. Dorababu M. Goel R. K. Bhattacharya S. K. (2002). Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats. Phytomedicine9, 207–211. 10.1078/0944-7113-00116

  • CrossRef
  • Google Scholar

• 275

  Saiyudthong S. Marsden C. A. (2011). Acute effects of bergamot oil on anxiety-related behaviour and corticosterone level in rats. Phytother. Res.25, 858–862. 10.1002/ptr.3325

  • CrossRef
  • Google Scholar

• 276

  Sakakibara H. Yoshino S. Kawai Y. Terao J. (2008). Antidepressant-like effect of onion (Allium cepa L.) powder in a rat behavioral model of depression. Biosci. Biotechnol. Biochem.72, 94–100. 10.1271/bbb.70454

  • CrossRef
  • Google Scholar

• 277

  Salehi B. Venditti A. Sharifi-Rad M. Kręgiel D. Sharifi-Rad J. Durazzo A. et al (2019). The therapeutic potential of apigenin. Int. J. Mol. Sci.20, 1305. 10.3390/ijms20061305

  • CrossRef
  • Google Scholar

• 278

  Santos T. Cd. Gomes T. M. Pinto B. A. S. Camara A. L. Paes A. MdA. (2018). Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer's disease therapy. Front. Pharmacol.9, 1192. 10.3389/fphar.2018.01192

  • CrossRef
  • Google Scholar

• 279

  Sarris J. (2007). Herbal medicines in the treatment of psychiatric disorders: A systematic review. Phytother. Res.21, 703–716. 10.1002/ptr.2187

  • CrossRef
  • Google Scholar

• 280

  Sarris J. Kavanagh D. J. (2009). Kava and st. John's wort: Current evidence for use in mood and anxiety disorders. J. Altern. Complement. Med.15, 827–836. 10.1089/acm.2009.0066

  • CrossRef
  • Google Scholar

• 281

  Sarris J. O’Neil A. Coulson C. E. Schweitzer I. Berk M. (2014). Lifestyle medicine for depression. BMC Psychiatry14, 1–13. 10.1186/1471-244X-14-107

  • CrossRef
  • Google Scholar

• 282

  Sartori S. B. Singewald N. (2019). Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol. Ther.204, 107402. 10.1016/j.pharmthera.2019.107402

  • CrossRef
  • Google Scholar

• 283

  Schmidt M. Betti G. Hensel A. (2007). Saffron in phytotherapy: Pharmacology and clinical uses. Wien. Med. Wochenschr.157, 315–319. 10.1007/s10354-007-0428-4

  • CrossRef
  • Google Scholar

• 284

  Sergides C. Chirilă M. Silvestro L. Pitta D. Pittas A. (2016). Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp. Ther. Med.11, 164–170. 10.3892/etm.2015.2895

  • CrossRef
  • Google Scholar

• 285

  Shaito A. Posadino A. M. Younes N. Hasan H. Halabi S. Alhababi D. et al (2020). Potential adverse effects of resveratrol: A literature review. Int. J. Mol. Sci.21, 2084. 10.3390/ijms21062084

  • CrossRef
  • Google Scholar

• 286

  Shandilya A. Mehan S. Kumar S. Sethi P. Narula A. S. Alshammari A. et al (2022). Activation of IGF-1/GLP-1 signalling via 4-hydroxyisoleucine prevents motor neuron impairments in experimental ALS-rats exposed to methylmercury-induced neurotoxicity. Molecules27, 3878. 10.3390/molecules27123878

  • CrossRef
  • Google Scholar

• 287

  Shao C. Yuan J. Liu Y. Qin Y. Wang X. Gu J. et al (2020). Epileptic brain fluorescent imaging reveals apigenin can relieve the myeloperoxidase-mediated oxidative stress and inhibit ferroptosis. Proc. Natl. Acad. Sci. U. S. A.117, 10155–10164. 10.1073/pnas.1917946117

  • CrossRef
  • Google Scholar

• 288

  Sharifi-Rad M. Lankatillake C. Dias D. A. Docea A. O. Mahomoodally M. F. Lobine D. et al (2020). Impact of natural compounds on neurodegenerative disorders: From preclinical to pharmacotherapeutics. J. Clin. Med.9, 1061. 10.3390/jcm9041061

  • CrossRef
  • Google Scholar

• 289

  Sharma R. Garg N. Verma D. Rathi P. Sharma V. Kuca K. et al (2021). “Indian medicinal plants as drug leads in neurodegenerative disorders,” in Nutraceuticals in brain health and beyond (Academic Press), 1–45. 10.1016/B978-0-12-820593-8.00004-5

  • CrossRef
  • Google Scholar

• 290

  Sharma R. Kabra A. Rao M. M. Prajapati P. K. (2018). Herbal and holistic solutions for neurodegenerative and depressive disorders: Leads from ayurveda. Curr. Pharm. Des.24, 2597–2608. 10.2174/1381612824666180821165741

  • CrossRef
  • Google Scholar

• 291

  Sharma R. Kuca K. Nepovimova E. Kabra A. Rao M. M. Prajapati P. K. (2019). Traditional ayurvedic and herbal remedies for alzheimer’s disease: From bench to bedside. Expert Rev. Neurother.19, 359–374. 10.1080/14737175.2019.1596803

  • CrossRef
  • Google Scholar

• 292

  Sharma R. Singla R. K. Banerjee S. Sinha B. Shen B. Sharma R. (2022). Role of shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies. Neurosci. Biobehav. Rev.140, 104795. 10.1016/j.neubiorev.2022.104795

  • CrossRef
  • Google Scholar

• 293

  Shirbandi K. Khalafi M. Mirza-Aghazadeh-Attari M. Tahmasbi M. Shahvandi H. K. Javanmardi P. et al (2021). Accuracy of deep learning model-assisted amyloid positron emission tomography scan in predicting alzheimer's disease: A systematic review and meta-analysis. Inf. Med. Unlocked25, 100710. 10.1016/j.imu.2021.100710

  • CrossRef
  • Google Scholar

• 294

  Sibi P. I. Meera P. (2013). In silico docking analysis of constituents of Zingiber officinale as antidepressant. J. Pharmacogn. Phytother.5, 101–105. 10.5897/JPP2013.0280

  • CrossRef
  • Google Scholar

• 295

  Singh B. Bhat T. K. Singh B. (2003). Potential therapeutic applications of some antinutritional plant secondary metabolites. J. Agric. Food Chem.51, 5579–5597. 10.1021/jf021150r

  • CrossRef
  • Google Scholar

• 296

  Singh G. K. Garabadu D. Muruganandam A. V. Joshi V. K. Krishnamurthy S. (2009). Antidepressant activity of Asparagus racemosus in rodent models. Pharmacol. Biochem. Behav.91, 283–290. 10.1016/j.pbb.2008.07.010

  • CrossRef
  • Google Scholar

• 297

  Singh R. P. Jain R. Mishra R. Tiwari P. (2012). Antidepressant activity of hydroalcoholic extract of Zingiber officinale. Int. Res. J. Pharm.3, 149–151. 10.2174/1871527321666220128091408

  • CrossRef
  • Google Scholar

• 298

  Singh R. Ramakrishna R. Bhateria M. Bhatta R. S. (2014). In vitro evaluation of Bacopa monniera extract and individual constituents on human recombinant monoamine oxidase enzymes. Phytother. Res.28, 1419–1422. 10.1002/ptr.5116

  • CrossRef
  • Google Scholar

• 299

  Singla R. K. Joon S. Shen L. Shen B. (2021). Translational informatics for natural products as antidepressant agents. Front. Cell Dev. Biol.9, 738838. 10.3389/fcell.2021.738838

  • CrossRef
  • Google Scholar

• 300

  Singla R. K. Scotti L. Dubey A. K. (2017). In silico studies revealed multiple neurological targets for the antidepressant molecule ursolic acid. Curr. Neuropharmacol.15, 1100–1106. 10.2174/1570159X14666161229115508

  • CrossRef
  • Google Scholar

• 301

  Siqueira I. R. Cimarosti H. Fochesatto C. Nunes D. S. Salbego C. Elisabetsky E. et al (2004). Neuroprotective effects of Ptychopetalum olacoides Bentham (Olacaceae) on oxygen and glucose deprivation induced damage in rat hippocampal slices. Life Sci.75, 1897–1906. 10.1016/j.lfs.2004.06.001

  • CrossRef
  • Google Scholar

• 302

  Sivanantharajah L. Mudher A. (2022). Curcumin as a holistic treatment for tau pathology. Front. Pharmacol.13, 903119. 10.3389/fphar.2022.903119

  • CrossRef
  • Google Scholar

• 303

  Smolilo D. J. Costa M. Hibberd T. J. Brookes S. J. Wattchow D. A. Spencer N., J. (2019). Distribution, projections, and association with calbindin baskets of motor neurons, interneurons, and sensory neurons in Guinea-pig distal colon. J. Comp. Neurol.527, 1140–1158. 10.1002/cne.24594

  • CrossRef
  • Google Scholar

• 304

  Song Q. Peng S. Zhu X. (2021). Baicalein protects against MPP+/MPTP-induced neurotoxicity by ameliorating oxidative stress in SH-SY5Y cells and mouse model of Parkinson’s disease. Neurotoxicology87, 188–194. 10.1016/j.neuro.2021.10.003

  • CrossRef
  • Google Scholar

• 305

  Spector P. E. Fox S. Penney L. M. Bruursema K. Goh A. Kessler S. (2006). The dimensionality of counterproductivity: Are all counterproductive behaviors created equal?J. Vocat. Behav.68, 446–460. 10.1016/j.jvb.2005.10.005

  • CrossRef
  • Google Scholar

• 306

  Speers A. B. Cabey K. A. Soumyanath A. Wright K. M. (2021). Effects of Withania somnifera (ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Curr. Neuropharmacol.19, 1468–1495. 10.2174/1570159X19666210712151556

  • CrossRef
  • Google Scholar

• 307

  Srinivasan E. Chandrasekhar G. Rajasekaran R. (2022). Probing the polyphenolic flavonoid, morin as a highly efficacious inhibitor against amyloid (A4V) mutant SOD1 in fatal Amyotrophic Lateral Sclerosis. Arch. Biochem. Biophys.727, 109318. 10.1016/j.abb.2022.109318

  • CrossRef
  • Google Scholar

• 308

  Srinivasan G. Ranjith C. Vijayan K. (2008). Identification of chemical compounds from the leaves of Leea indica. Acta Pharm.58, 207–214. 10.2478/v10007-008-0002-7

  • CrossRef
  • Google Scholar

• 309

  Srinivasan S. Gal J. Bachstetter A. Nelson P. T. (2022). Alpha adaptins show isoformspecific association with neurofibrillary tangles in Alzheimer's disease. Neuropathol. Appl. Neurobiol.48, 12776. 10.1111/nan.12776

  • CrossRef
  • Google Scholar

• 310

  Stanciu G. D. Luca A. Rusu R. N. Bild V. Beschea Chiriac S. I. Solcan C. et al (2020). Alzheimer’s disease pharmacotherapy in relation to cholinergic system involvement. Biomolecules10, 40. 10.3390/biom10010040

  • CrossRef
  • Google Scholar

• 311

  Stefanovski L. Meier J. M. Pai R. K. Triebkorn P. Lett T. Martin L. et al (2021). Bridging scales in alzheimer's disease: Biological framework for brain simulation with the virtual brain. Front. Neuroinform.15, 630172. 10.3389/fninf.2021.630172

  • CrossRef
  • Google Scholar

• 312

  Stough C. Lloyd J. Clarke J. Downey L. Hutchison C. Rodgers T. et al (2001). Nathan, P. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology156, 481–484. 10.1007/s002130100815

  • CrossRef
  • Google Scholar

• 313

  Su C. F. Jiang L. Zhang X. W. Iyaswamy A. Li M. (2021). Resveratrol in rodent models of Parkinson’s disease: A systematic review of experimental studies. Front. Pharmacol.12, 644219. 10.3389/fphar.2021.644219

  • CrossRef
  • Google Scholar

• 314

  Su C. Zhang D. Truong J. Jiang C. Lee S. Jarouche M. et al (2013). Effects of a novel herbal formulation JSK on acute spinal cord injury in rats. Restor. Neurol. Neurosci.31, 597–617. 10.3233/RNN-120303

  • CrossRef
  • Google Scholar

• 315

  Subarnas A. Oshima Y. Ohizumi Y. (1992). An antidepressant principle of Lobelia inflata L. (Campanulaceae). J. Pharm. Sci.81, 620–621. 10.1002/jps.2600810705

  • CrossRef
  • Google Scholar

• 316

  Subarnas A. Tadano T. Nakahata N. Arai Y. Kinemuchi H. Oshima Y. et al (1993). A possible mechanism of antidepresant activity of beta-amyrin palmitate isolated from Lobelia inflata leaves in the forced swimming test. Life Sci.52, 289–296. 10.1016/0024-3205(93)90220-W

  • CrossRef
  • Google Scholar

• 317

  Subhan F. Karim N. Gilani A. H. Sewell R. D. (2010). Terpenoid content of Valerianawallichii extracts and antidepressant-like response profiles. Phytother. Res.24, 686–691. 10.1002/ptr.2980

  • CrossRef
  • Google Scholar

• 318

  Tabeshpour J. Mehri S. Shaebani Behbahani F. Hosseinzadeh H. (2018). Protective effects of Vitis vinifera (grapes) and one of its biologically active constituents, resveratrol, against natural and chemical toxicities: A comprehensive review. Phytother. Res.32, 2164–2190. 10.1002/ptr.6168

  • CrossRef
  • Google Scholar

• 319

  Takemoto Y. Kishi C. Ehira H. Matsui N. Yamaguchi T. Yoshioka Y. et al (2022). Inhaled turmerones can be incorporated in the organs via pathways different from oral administration and can affect weight-gain of mice. Sci. Rep.12, 1–8. 10.1038/s41598-022-15168-9

  • CrossRef
  • Google Scholar

• 320

  Thomas I. Timothy D. G. Veltmeyer J. O'Connor K. (2022). “Treatment of major depressive disorder and suicidal ideations through stimulation of hippocampal neurogenesis utilizing plant-based approaches,”. US20220175701.

  • Google Scholar

• 321

  Thomford N. E. Senthebane D. A. Rowe A. Munro D. Seele P. Maroyi A. et al (2018). Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. Int. J. Mol. Sci.19, 1578. 10.3390/ijms19061578

  • CrossRef
  • Google Scholar

• 322

  Thuraisingam S. Salim N. Azmi I. D. Kartinee N. (2022). Development of nanoemulsion containing Centella asiatica crude extract as a promising drug delivery system for epilepsy treatment. Biointerface Res. Appl. Chem.13, 17. 10.33263/BRIAC131.017

  • CrossRef
  • Google Scholar

• 323

  Toyoshima Y. Takahashi H. (2014). TDP-43 pathology in polyglutamine diseases: With reference to amyotrphic lateral sclerosis. Neuropathology34, 77–82. 10.1111/neup.12053

  • CrossRef
  • Google Scholar

• 324

  Träger U. Andre R. Magnusson-Lind A. Miller J. R. Connolly C. Weiss A. et al (2015). Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiol. Dis.73, 388–398. 10.1016/j.nbd.2014.10.012

  • CrossRef
  • Google Scholar

• 325

  Tungmunnithum D. Drouet S. Hano C. (2022). Phytochemical diversity and antioxidant potential of natural populations of Nelumbo nucifera Gaertn. throughout the floristic regions in Thailand. Molecules27, 681. 10.3390/molecules27030681

  • CrossRef
  • Google Scholar

• 326

  Usman M. B. Ojha S. Jha S. K. Chellappan D. K. Gupta G. Singh S. K. et al (2022). Biological databases and tools for neurological disorders. J. Integr. Neurosci.21, 41. 10.31083/j.jin2101041

  • CrossRef
  • Google Scholar

• 327

  Utomo R. Y. Sugie A. Okada S. Miura K. Nakamura H. (2022). Detoxification of amyloid β fibrils by curcumin derivatives and their verification in a Drosophila Alzheimer’s model. Chem. Commun.58, 2576–2579. 10.1039/D1CC07000B

  • CrossRef
  • Google Scholar

• 328

  Vaijnath S. S. Suraj A. (2019). Development and evaluation of wedelolactone nasal formulation for antiepileptic activity, IN201921009898.

  • Google Scholar

• 329

  Van Diermen D. Marston A. Bravo J. Reist M. Carrupt P. A. Hostettmann K. (2009). Monoamine oxidase inhibition by Rhodiola rosea L. roots. J. Ethnopharmacol.122, 397–401. 10.1016/j.jep.2009.01.007

  • CrossRef
  • Google Scholar

• 330

  Venâncio E. T. Rocha N. F. Rios E. R. Feitosa M. L. Linhares M. I. Melo F. H. et al (2011). Anxiolytic-like effects of standardized extract of Justicia pectoralis (SEJP) in mice: Involvement of GABA/benzodiazepine in receptor. Phytother. Res.25, 444–450. 10.1002/ptr.3274

  • CrossRef
  • Google Scholar

• 331

  Verstraeten A. Theuns J. VanBroeckhoven C. (2015). Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet.31, 140–149. 10.1016/j.tig.2015.01.004

  • CrossRef
  • Google Scholar

• 332

  Viana A. do Rego J. C. von Poser G. Ferraz A. Heckler A. P. Costentin J. et al (2005). The antidepressant-like effect of Hypericum caprifoliatum Cham &Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake. Neuropharmacology49, 1042–1052. 10.1016/j.neuropharm.2005.06.002

  • CrossRef
  • Google Scholar

• 333

  Vidyanti A. N. Awaliyah M. T. Fauzi A. R. Harahap I. S. Mulya D. P. (2022). Dementia in a patient with autoimmune disease and hypercoagulable state worsened by COVID-19 vaccination: A case report. Ann. Med. Surg.78, 103886. 10.1016/j.amsu.2022.103886

  • CrossRef
  • Google Scholar

• 334

  Vijh D. Imam M. Haque M. Das S. Islam A. Malik M. (2022). Network pharmacology and bioinformatics approach reveals the therapeutic mechanism of action of curcumin in Alzheimer disease. Res. Sq. Prepr. version. 1. 1.

  • Google Scholar

• 335

  Villa F. A. Gerwick L. (2010). Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders. Immunopharmacol. Immunotoxicol.32, 228–237. 10.3109/08923970903296136

  • CrossRef
  • Google Scholar

• 336

  Villoslada P. Moreno B. Melero I. Pablos J. L. Martino G. Uccelli A. et al (2008). Immunotherapy for neurological diseases. Clin. Immunol.128, 294–305. 10.1016/j.clim.2008.04.003

  • CrossRef
  • Google Scholar

• 337

  Viswambharan V. Thanseem I. Vasu M. M. Poovathinal S. A. Anitha A. (2017). miRNAs as biomarkers of neurodegenerative disorders. Biomark. Med.11, 151–167. 10.2217/bmm-2016-0242

  • CrossRef
  • Google Scholar

• 338

  Wan C. Chen G. Fu Y. Wang M. Matsuhisa N. Pan S. et al (2018). An artificial sensory neuron with tactile perceptual learning. Adv. Mat.30, 1801291. 10.1002/adma.201801291

  • CrossRef
  • Google Scholar

• 339

  Wang N. Pan X. Y. Zhu H. K. Guo Y. H. Qian H. (2021). Chicoric acid prevents neurodegeneration via microbiota-gut-brain axis in a mouse Parkinson’s disease model. bioRxiv. 1. 1. 10.1101/2021.05.03.442390

  • CrossRef
  • Google Scholar

• 340

  Wang P. S. Aguilar-Gaxiola S. Alonso J. Angermeyer M. C. Borges G. Bromet E. J. et al (2007). Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet370, 841–850. 10.1016/S0140-6736(07)61414-7

  • CrossRef
  • Google Scholar

• 341

  Wang T.-Y. Li Q. Bi K.-S. (2018). Bioactive flavonoids in medicinal plants: Structure, activity and biological fate. Asian J. Pharm. Sci.13, 12–23. 10.1016/j.ajps.2017.08.004

  • CrossRef
  • Google Scholar

• 342

  Wang W. Hu X. Zhao Z. Liu P. Hu Y. Zhou J. et al (2008). Antidepressant-like effects of liquiritin and isoliquiritin from Glycyrrhiza uralensis in the forced swimming test and tail suspension test in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry32, 1179–1184. 10.1016/j.pnpbp.2007.12.021

  • CrossRef
  • Google Scholar

• 343

  Wang Y. Wei N. Li X. (2020). Preclinical evidence and possible mechanisms of baicalein for rats and mice with Parkinson's disease: A systematic review and meta-analysis. Front. Aging Neurosci.12, 277. 10.3389/fnagi.2020.00277

  • CrossRef
  • Google Scholar

• 344

  Werner M. H. Olanow C. W. (2022). Parkinson's disease modification through abl kinase inhibition: An opportunity. Mov. Disord.37, 6–15. 10.1002/mds.28858

  • CrossRef
  • Google Scholar

• 345

  Wichansawakun S. Chupisanyarote K. Wongpipathpong W. Kaur G. Buttar H. S. (2022). Functional foods and nutraceuticals in metabolic and non-communicable diseases. Academic Press, 533–549. 10.1016/B978-0-12-819815-5.00028-8Antioxidant diets and functional foods attenuate dementia and cognition in elderly subjects

  • CrossRef
  • Google Scholar

• 346

  Woelk H. Arnoldt K. H. Kieser M. Hoerr R. (2007). Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J. Psychiatr. Res.41, 472–480. 10.1016/j.jpsychires.2006.05.004

  • CrossRef
  • Google Scholar

• 347

  Wojcik G. M. Masiak J. Kawiak A. Schneider P. Kwasniewicz L. Polak N. et al (2018). New protocol for quantitative analysis of brain cortex electroencephalographic activity in patients with psychiatric disorders. Front. Neuroinform.12, 27. 10.3389/fninf.2018.00027

  • CrossRef
  • Google Scholar

• 348

  Wu Y. Chen Q. Wen B. Wu N. He B. Chen J. (2021). Berberine reduces Aβ42 deposition and tau hyperphosphorylation via ameliorating endoplasmic reticulum stress. Front. Pharmacol.12, 640758. 10.3389/fphar.2021.640758

  • CrossRef
  • Google Scholar

• 349

  Xie W. Zhang X. Wang T. Hu J. (2007). Botany, traditional uses, phytochemistry and pharmacology of Apocynum venetum L.(Luobuma): A review. J. Ethnopharmacol.141, 1–8. 10.1016/j.jep.2012.02.003

  • CrossRef
  • Google Scholar

• 350

  Xu B. Wang X. Xu Z. Li Q. Quan J. (2022). N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson’s disease. Neurosci. Lett.784, 136751. 10.1016/j.neulet.2022.136751

  • CrossRef
  • Google Scholar

• 351

  Xu K. Li Y. Allen E. G. Jin P. (2021). Therapeutic development for CGG repeat expansion-associated neurodegeneration. Front. Cell. Neurosci.15, 655568. 10.3389/fncel.2021.655568

  • CrossRef
  • Google Scholar

• 352

  Xu Q. Pan Y. Yi L. T. Li Y. C. Mo S. F. Jiang F. X. et al (2008). Antidepressant-like effects of psoralen isolated from the seeds of Psoralea corylifolia in the mouse forced swimming test. Biol. Pharm. Bull.31, 1109–1114. 10.1248/bpb.31.1109

  • CrossRef
  • Google Scholar

• 353

  Yang J. Fang L. Lu H. Liu C. Wang J. Wu D. et al (2022). Walnut-derived peptide enhances mitophagy via JNK-mediated PINK1 activation to reduce oxidative stress in HT-22 cells. J. Agric. Food Chem.70, 2630–2642. 10.1021/acs.jafc.2c00005

  • CrossRef
  • Google Scholar

• 354

  Yang J. Q. Wang R. Ren Y. Mao J. Y. Wang Z. P. Zhou Y. et al (2020). Neuromorphic engineering: From biological to spike-based hardware nervous systems. Adv. Mat.32, 2003610. 10.1002/adma.202003610

  • CrossRef
  • Google Scholar

• 355

  Yi L. T. Li J. Geng D. Liu B. B. Fu Y. Tu J. Q. et al (2013). Essential oil of Perilla frutescens-induced change in hippocampal expression of brain-derived neurotrophic factor in chronic unpredictable mild stress in mice. J. Ethnopharmacol.147, 245–253. 10.1016/j.jep.2013.03.015

  • CrossRef
  • Google Scholar

• 356

  Yi L. T. Li Y. C. Pan Y. Li J. M. Xu Q. Mo S. F. et al (2008). Antidepressant-like effects of psoralidin isolated from the seeds of Psoralea corylifolia in the forced swimming test in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry32, 510–519. 10.1016/j.pnpbp.2007.10.005

  • CrossRef
  • Google Scholar

• 357

  Yiannopoulou K. G. Papageorgiou S. G. (2013). Current and future treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord.6, 19–33. 10.1177/1756285612461679

  • CrossRef
  • Google Scholar

• 358

  Yin J. Xing H. Ye J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism.57, 712–717. 10.1016/j.metabol.2008.01.013

  • CrossRef
  • Google Scholar

• 359

  Yoon J. J. Jeong J. W. Choi E. O. Kim M. J. Hwang-Bo H. Kim H. J. et al (2017). Protective effects of Scutellaria baicalensis Georgi against hydrogen peroxide-induced DNA damage and apoptosis in HaCaT human skin keratinocytes. EXCLI J.16, 426–438. 10.17179/excli2016-817

  • CrossRef
  • Google Scholar

• 360

  Yoshitake T. Yoshitake S. Kehr J. (2010). The Ginkgo biloba extract EGb 761® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br. J. Pharmacol.159, 659–668. 10.1111/j.1476-5381.2009.00580.x

  • CrossRef
  • Google Scholar

• 361

  Yousaf M. Chang D. Liu Y. Liu T. Zhou X. (2022). Neuroprotection of cannabidiol, its synthetic derivatives and combination preparations against microglia-mediated neuroinflammation in neurological disorders. Molecules27, 4961. 10.3390/molecules27154961

  • CrossRef
  • Google Scholar

• 362

  Yu Y. Shen Q. Lai Y. Park S. Y. Ou X. Lin D. et al (2018). Anti-inflammatory effects of curcumin in microglial cells. Front. Pharmacol.9, 386. 10.3389/fphar.2018.00386

  • CrossRef
  • Google Scholar

• 363

  Yu Z. F. Kong L. D. Chen Y. (2022). Antidepressant activity of aqueous extracts of Curcuma longa in mice. J. Ethnopharmacol.83, 161–165. 10.1016/S0378-8741(02)00211-8

  • CrossRef
  • Google Scholar

• 364

  Zaazaa A. M. Daoud N. N. El-Gendy O. A. Al-Shafei A. I. (2022). Neuroprotective role of Bacopa monnieri extract in modulating depression in an experimental rat model. J. Affect. Disord.308, 229–235. 10.1016/j.jad.2022.04.021

  • CrossRef
  • Google Scholar

• 365

  Zarneshan S. N. Fakhri S. Khan H. (2022). Targeting akt/CREB/BDNF signaling pathway by ginsenosides in neurodegenerative diseases: A mechanistic approach. Pharmacol. Res.177, 106099. 10.1016/j.phrs.2022.106099

  • CrossRef
  • Google Scholar

• 366

  Zhang B. Zhao J. Wang Z. Guo P. Liu A. Du G. (2021). Identification of multi-target anti-ad chemical constituents from traditional Chinese medicine formulae by integrating virtual screening and in vitro validation. Front. Pharmacol.12, 709607. 10.3389/fphar.2021.709607

  • CrossRef
  • Google Scholar

• 367

  Zhang L.-X. Li C.-X. Kakar M. U. Khan M. S. Wu P.-F. Amir R. M. et al (2021). Resveratrol (RV): A pharmacological review and call for further research. Biomed. Pharmacother.143, 112164. 10.1016/j.biopha.2021.112164

  • CrossRef
  • Google Scholar

• 368

  Zhang S. Gong T. T. Liu F. H. Jiang Y. T. Sun H. Ma X. X. et al (2019). Global, regional, and national burden of endometrial cancer, 1990–2017: Results from the global burden of disease study. Front. Oncol.9, 1440. 10.3389/fonc.2019.01440

  • CrossRef
  • Google Scholar

• 369

  Zhang Z. Q. Yuan L. Yang M. Luo Z. P. Zhao Y. M. (2002). The effect of Morinda officinalis How, a Chinese traditional medicinal plant, on the DRL 72-s schedule in rats and the forced swimming test in mice. Pharmacol. Biochem. Behav.72, 39–43. 10.1016/S0091-3057(01)00730-4

  • CrossRef
  • Google Scholar

• 370

  Zhao H. Wang C. Zhao N. Li W. Yang Z. Liu X. et al (2018). Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling. J. Chromatogr. B Anal. Technol. Biomed. Life Sci.1081, 101–108. 10.1016/j.jchromb.2018.01.025

  • CrossRef
  • Google Scholar

• 371

  Zhao X. Kong D. Zhou Q. Wei G. Song J. Liang Y. et al (2021). Baicalein alleviates depression-like behavior in rotenone-induced Parkinson's disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomed. Pharmacother.140, 111556. 10.1016/j.biopha.2021.111556

  • CrossRef
  • Google Scholar

• 372

  Zhao Z. Wang W. Guo H. Zhou D. (2008). Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behav. Brain Res.194, 108–113. 10.1016/j.bbr.2008.06.030

  • CrossRef
  • Google Scholar

• 373

  Zheng M. Fan Y. Shi D. Liu C. (2013). Antidepressant-like effect of flavonoids extracted from Apocynum venetum leaves on brain monoamine levels and dopaminergic system. J. Ethnopharmacol.147, 108–113. 10.1016/j.jep.2013.02.015

  • CrossRef
  • Google Scholar

• 374

  Zhou D. Jin H. Lin H. B. Yang X. M. Cheng Y. F. Deng F. J. et al (2010). Antidepressant effect of the extracts from Fructus akebiae. Pharmacol. Biochem. Behav.94, 488–495. 10.1016/j.pbb.2009.11.003

  • CrossRef
  • Google Scholar

• 375

  Zhou N. Gu X. Zhuang T. Xu Y. Yang L. Zhou M. (2020). Gut microbiota: A pivotal hub for polyphenols as antidepressants. J. Agric. Food Chem.68, 6007–6020. 10.1021/acs.jafc.0c01461

  • CrossRef
  • Google Scholar

• 376

  Zlotnik G. Vansintjan A. (2019). Memory: An extended definition. Front. Psychol.10, 2523. 10.3389/fpsyg.2019.02523

  • CrossRef
  • Google Scholar

• 377

  Zoey F. L. Palanivel M. Padmanabhan P. Gulyás B. (2021). Parkinson’s disease: A nanotheranostic approach targeting alpha-synuclein aggregation. Front. Cell Dev. Biol.9. 10.3389/fcell.2021.707441707441

  • CrossRef
  • Google Scholar

• 378

  Zucchella C. Sinforiani E. Tamburin S. Federico A. Mantovani E. Bernini S. et al (2018). The multidisciplinary approach to Alzheimer's disease and dementia. A narrative review of non-pharmacological treatment. Front. Neurol.9, 1058. 10.3389/fneur.2018.01058

  • CrossRef
  • Google Scholar